Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2019 | Mar. 27, 2020 | Jun. 28, 2019 | |
Document And Entity Information | |||
Entity Registrant Name | BioCorRx Inc. | ||
Entity Central Index Key | 0001443863 | ||
Document Type | 10-K | ||
Amendment Flag | false | ||
Entity Voluntary Filers | No | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Small Business | true | ||
Entity Shell Company | false | ||
Entity Emerging Growth Company | false | ||
Entity Current Reporting Status | Yes | ||
Document Period End Date | Dec. 31, 2019 | ||
Entity Filer Category | Non-accelerated Filer | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2019 | ||
Entity Common Stock Shares Outstanding | 5,339,757 | ||
Entity Public Float | $ 11,193,488 | ||
EntityFileNumber | 000-54208 | ||
EntityAddressAddressLine1 | 2390 East Orangewood Avenue | ||
EntityAddressAddressLine2 | Suite 500 | ||
EntityAddressPostalZipCode | 92806 | ||
EntityTaxIdentificationNumber | 900967447 | ||
EntityAddressCityOrTown | Anaheim | ||
LocalPhoneNumber | 462-4880 | ||
CityAreaCode | 714 | ||
EntityAddressStateOrProvince | CALIFORNIA |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash | $ 2,645,852 | $ 279,772 |
Accounts receivable, net | 750 | 8,000 |
Grant receivable | 186,668 | |
Prepaid expenses | 213,283 | 31,458 |
Total current assets | 3,046,553 | 319,230 |
Property and equipment, net | 148,300 | 44,369 |
Right to use assets | 458,707 | |
Other assets: | ||
Patents,net | 13,736 | 15,200 |
Intellectual property, net | 224,010 | 236,000 |
Deposits, long term | 41,936 | 13,422 |
Total other assets | 279,682 | 264,622 |
Total assets | 3,933,242 | 628,221 |
Current liabilities: | ||
Accounts payable and accrued expenses, including related party payables of $391,209 and $32,318, respectively | 2,027,380 | 1,554,652 |
Deferred revenue, short term | 134,924 | 209,474 |
Lease liability, short term | 76,977 | |
Convertible notes payable, net of debt discount of $0 and $656,231 | 3,503,769 | |
Notes payable, net of debt discounts of $0 and $127,419 | 21,480 | 569,061 |
Notes payable, related party | 290,110 | 290,110 |
Total current liabilities | 2,550,871 | 6,127,066 |
Long term liabilities: | ||
Royalty obligation - net of discount of $6,812,318 and $0, related parties | 1,909,782 | |
Deferred revenue, long term | 103,313 | 207,523 |
Lease liabilities, Long term | 428,162 | |
Total liabilities | 4,992,128 | 6,334,589 |
Commitments and contingencies | ||
Deficit: | ||
Preferred stock, no par value, 600,000 authorized | ||
Common stock, $0.001 par value; 750,000,000 shares authorized, 5,326,852 and 2,597,347 shares issued and outstanding as of December 31, 2019 and 2018, respectively | 5,327 | 2,597 |
Common stock subscribed | 100,000 | 100,000 |
Additional paid in capital | 60,111,429 | 49,418,356 |
Accumulated deficit | (61,216,080) | (55,176,450) |
Total deficit attributable to BioCorRx, Inc. | (977,708) | (5,633,881) |
Non-controlling interest | (81,178) | (72,487) |
Total deficit | (1,058,886) | (5,706,368) |
Total liabilities and deficit | 3,933,242 | 628,221 |
Series A Preferred Stock [Member] | ||
Deficit: | ||
Preferred stock, no par value, 600,000 authorized | 16,000 | 16,000 |
Series B Preferred Stock [Member] | ||
Deficit: | ||
Preferred stock, no par value, 600,000 authorized | $ 5,616 | $ 5,616 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
Current liabilities: | ||
Related party payables | $ 391,209 | $ 32,318 |
Convertible notes payable, net of debt discount | 0 | 656,231 |
Notes payable, net of debt discounts | 0 | 127,419 |
Royalty obligation - related parties, net of discount | $ 6,812,318 | $ 0 |
Deficit: | ||
Preferred Stock, Par Value | ||
Preferred Stock, Shares Authorized | 600,000 | 600,000 |
Common Stock, Par Value | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 750,000,000 | 750,000,000 |
Common Stock, Shares Issued | 5,326,852 | 2,597,347 |
Common Stock, Shares Outstanding | 5,326,852 | 2,597,347 |
Series A Preferred Stock [Member] | ||
Deficit: | ||
Preferred Stock, Par Value | ||
Preferred Stock, Shares Authorized | 80,000 | 80,000 |
Preferred Stock, Shares Issued | 80,000 | 80,000 |
Preferred Stock, Shares Outstanding | 80,000 | 80,000 |
Series B Preferred Stock [Member] | ||
Deficit: | ||
Preferred Stock, Par Value | ||
Preferred Stock, Shares Authorized | 160,000 | 160,000 |
Preferred Stock, Shares Issued | 160,000 | 160,000 |
Preferred Stock, Shares Outstanding | 160,000 | 160,000 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||
Revenues, net | $ 240,259 | $ 376,656 |
Operating expenses: | ||
Cost of implants and other costs | 81,670 | 170,953 |
Research and development | 1,125,098 | 151,768 |
Selling, general and administrative | 4,565,346 | 4,422,600 |
Impairment of acquired license | 250,000 | |
Depreciation and amortization | 29,413 | 7,353 |
Total operating expenses | 5,801,527 | 5,002,674 |
Loss from operations | (5,561,268) | (4,626,018) |
Other income (expenses): | ||
Interest expense, net | (1,622,426) | (1,959,207) |
Gain on settlement of debt | 847 | |
Grant income | 1,091,061 | |
Loss on sale of fixed assets | (1,902) | |
Other miscellaneous income | 46,214 | |
Total other income (expenses) | (487,053) | (1,958,360) |
Net loss before provision for income taxes | (6,048,321) | (6,584,378) |
Income taxes | ||
Net Loss | (6,048,321) | (6,584,378) |
Non-controlling interest | 8,691 | 72,487 |
Net loss attributable to BioCorRx Inc. | $ (6,039,630) | $ (6,511,891) |
Net loss per common share, basic and diluted | $ (1.71) | $ (2.60) |
Weighted average number of common shares outstanding, basic and diluted | 3,523,208 | 2,506,229 |
CONSOLIDATED STATEMENT OF STOCK
CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY - USD ($) | Total | Series A Convertible Preferred Stock [Member] | Series B Convertible Preferred Stock [Member] | Common Stock [Member] | Common Stock Subscribed [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Noncontrolling Interest [Member] | Retained Earnings [Member] |
Balance, shares at Dec. 31, 2017 | 80,000 | 160,000 | 2,440,863 | ||||||
Balance, amount at Dec. 31, 2017 | $ 16,000 | $ 5,616 | $ 2,441 | $ 100,000 | $ 44,823,541 | $ (48,840,534) | $ (3,892,936) | ||
Effect of adoption of Accounting Codification Standard 2017-11, anti-dilution of warrant | 175,975 | 175,975 | |||||||
Common stock issued for services rendered, Shares | 40,248 | ||||||||
Common stock issued for services rendered, Amount | $ 40 | 457,690 | 457,730 | ||||||
Common stock issued for services accrued in 2017, Shares | 10,000 | ||||||||
Common stock issued for services accrued in 2017, Amount | $ 10 | (10) | |||||||
Sale of common stock, Shares | 75,000 | ||||||||
Sale of common stock, Amount | $ 75 | 1,399,925 | 1,400,000 | ||||||
Common stock issued in connection with notes payable, Shares | 6,000 | ||||||||
Common stock issued in connection with notes payable, Amount | $ 6 | 61,744 | 61,750 | ||||||
Common stock issued in connection with notes payable extension, Shares | 1,000 | ||||||||
Common stock issued in connection with notes payable extension, Amount | $ 1 | 11,999 | 12,000 | ||||||
Common stock issued to settle outstanding accounts payable, Shares | 4,236 | 4,236 | |||||||
Common stock issued to settle outstanding accounts payable, Amount | $ 4 | 29,649 | 29,653 | ||||||
Common stock issued to acquire intellectual property, Shares | 20,000 | ||||||||
Common stock issued to acquire intellectual property, Amount | $ 20 | 225,980 | 226,000 | ||||||
Fair value of warrants issued in connection with notes payable | $ 58,411 | 58,441 | 58,441 | ||||||
Share-based compensation | 2,349,427 | 2,349,427 | |||||||
Net Income (Loss) | $ (6,511,891) | $ (72,487) | $ (6,584,378) | ||||||
Balance, shares at Dec. 31, 2018 | 80,000 | 160,000 | 2,597,347 | ||||||
Balance, amount at Dec. 31, 2018 | (5,706,368) | $ 16,000 | $ 5,616 | $ 2,597 | $ 100,000 | $ 49,418,356 | $ (55,176,450) | $ (72,487) | $ (5,706,368) |
Common stock issued for services rendered, Shares | 75,017 | ||||||||
Common stock issued for services rendered, Amount | $ 76 | 270,974 | 271,050 | ||||||
Sale of common stock, Shares | 22,222 | ||||||||
Sale of common stock, Amount | $ 22 | 99,978 | 100,000 | ||||||
Fair value of warrants issued in connection with notes payable | |||||||||
Share-based compensation | 1,694,653 | 1,694,653 | |||||||
Net Income (Loss) | $ (6,039,630) | $ (8,691) | (6,048,321) | ||||||
Common stock issued in connection with note conversion, Amount | $ 2,227 | 4,157,773 | 4,160,000 | ||||||
Common stock issued in connection with note conversion, Shares | 2,227,575 | ||||||||
Common stock issued in connection with subscription and royalty agreement, Shares | 400,000 | ||||||||
Common stock issued in connection with subscription and royalty agreement, Amount | $ 400 | 4,448,700 | 4,449,100 | ||||||
Interest expense paid with common stock, Amount | $ 4 | 20,996 | $ 21,000 | ||||||
Interest expense paid with common stock, Shares | 3,842 | ||||||||
Round up shares for reverse stock split, Amount | $ 1 | $ (1) | |||||||
Round up shares for reverse stock split, Shares | 849 | ||||||||
Balance, shares at Dec. 31, 2019 | 80,000 | 160,000 | 5,326,852 | ||||||
Balance, amount at Dec. 31, 2019 | $ (1,058,886) | $ 16,000 | $ 5,616 | $ 5,327 | $ 100,000 | $ 60,111,429 | $ (61,216,080) | $ (81,178) | $ (1,058,886) |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net Loss | $ (6,048,321) | $ (6,584,378) |
Adjustments to reconcile net loss to cash flows used in operating activities: | ||
Depreciation and amortization | 29,413 | 7,353 |
Amortization of discount on royalty obligation | 358,882 | |
Bad debt expense | 2,400 | 24,750 |
Interest expense paid with common stock | 21,000 | |
Amortization of debt discount | 783,650 | 1,530,470 |
Amortization of right-of-use asset | 67,091 | |
Impairment of licensing agreement | 250,000 | |
Loss on sale of fixed assets | 1,902 | |
Stock based compensation | 1,965,703 | 2,807,157 |
Common stock issued with loan extension | 12,000 | |
Gain on settlement of debt | (847) | |
Changes in operating assets and liabilities: | ||
Accounts receivable | 4,850 | (2,800) |
Other receivable | (186,668) | |
Prepaid expenses | (181,825) | (18,248) |
Accounts payable and accrued expenses | 473,490 | 385,616 |
deposits | (28,514) | |
Lease liabilities | (21,420) | |
Settlement payable | (15,000) | |
Deferred revenue | (178,760) | (221,696) |
Net cash used in operating activities | (2,937,127) | (1,825,623) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of patent | (15,200) | |
Purchase of intellectual property | (10,000) | |
Purchase of equipment | (122,593) | (30,747) |
Proceeds from sale of property and equipment | 800 | |
Net cash used in investing activities | (121,793) | (55,947) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from sale of common stock | 100,000 | 1,400,000 |
Proceeds from common stock subscription and royalty agreement | 6,000,000 | |
Proceeds from notes payable | 750,000 | |
Repayment of notes payable | (675,000) | |
Net cash provided by financing activities | 5,425,000 | 2,150,000 |
Net increase in cash | 2,366,080 | 268,430 |
Supplemental disclosures of cash flow information: | ||
Interest paid | 61,397 | |
Taxes paid | ||
Non cash financing activities: | ||
Record right to use assets per ASC 842, net of deferred rent | 525,798 | |
Record lease liability per ASC 842 | 526,559 | |
Common stock issued in connection with conversion of notes payable | 4,160,000 | |
Common stock issued in connection with issuance of notes payable | 61,750 | |
Common stock issued to acquire intellectual property | 226,000 | |
Fair value of warrants issued in connection with notes payable | 58,411 | |
Reclassify fair value of warrant liability upon adoption of ASU 2017-11 | 175,975 | |
Common stock issued to settle outstanding accounts payable | $ 29,653 |
BUSINESS
BUSINESS | 12 Months Ended |
Dec. 31, 2019 | |
BUSINESS | |
Note 1 - BUSINESS | BioCorRx Inc., through its subsidiaries, develops and provides innovative treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The full program officially launched October 1, 2019. The Company s majority owned subsidiary BioCorRx Pharmaceuticals Inc. is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Specifically, the Company is developing an injectable (BICX101) and implantable naltrexone (BICX102) with the goal of future regulatory approval with the Food and Drug Administration. On July 28, 2016, BioCorRx Inc. formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the newly formed sub issued 24.2% ownership to officers of BioCorRx Inc. retaining 75.8%. In 2018, BioCorRx Pharmaceuticals, Inc. began operating activities (Note 15). Effective January 22, 2019, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 100 shares of common stock. As a result, 259,984,655 shares of the Company's common stock were exchanged for 2,599,847 shares of the Company's common stock. These consolidated financial statements have been retroactively restated to reflect the reverse stock split (See Note 13). |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2019 | |
SIGNIFICANT ACCOUNTING POLICIES | |
Note 2 - SIGNIFICANT ACCOUNTING POLICIES | Basis of presentation The consolidated financial statements include the accounts of BioCorRx Inc. and its wholly owned subsidiary, Fresh Start Private, Inc. and its majority owned subsidiary, BioCorRx Pharmaceuticals, Inc. (hereafter referred to as the "Company" or "BioCorRx"). All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition The Company recognizes revenue in accordance with Financial Accounting Standards Board "FASB" Accounting Standards Codification "ASC" 606. A five-step analysis a must be met as outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. There were no changes to the Company's revenue recognition policy from the adoption of ASC 606. The Company has elected the following practical expedients in applying ASC 606: • Unsatisfied Performance Obligations - all performance obligations relate to contracts with a duration of less than one year. The Company has elected to apply the optional exemption provided in ASC 606 and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. • Contract Costs - all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. • Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component as the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. • Sales Tax Exclusion from the Transaction Price - the Company excludes from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer. • Shipping and Handling Activities - the Company elected to account for shipping and handling activities as a fulfillment cost rather than as a separate performance obligation. • Modified Retrospective Method - the Company adopted ASC 606 on January 1, 2018 utilizing the modified retrospective method allowing the Company to not retrospectively adjust prior periods. The Company applied the modified retrospective method only to contracts that were not completed at January 1, 2018 and accounted for the aggregate effect of any contract modifications upon adoption. The Company's net sales are disaggregated by product category. The sales/access fees consist of product sales, which is recognized upon the transfer of promised goods to customers. The distribution rights income consists of the income recognized from the amortization of distribution agreements entered into for its products. The membership/program fees are generated from the Company’s UnCraveRx™ Weight Loss Management Program, which is recognized upon the transfer of promised goods to customers. The following table presents our net sales by product category for the year ended December 31, 2019 and 2018: 2019 2018 Sales/access fees $ 29,150 $ 129,960 Distribution rights income 207,110 246,696 Membership/program fees 3,999 - Net sales $ 240,259 $ 376,656 Deferred revenue: The Company licenses proprietary products and protocols to customers under licensing agreements that allow those customers to access the products and protocols in services they provide to their customers during the term of the license agreement. The timing and amount of revenue recognized from license agreements depends upon a variety of factors, including the specific terms of each agreement. Such agreements are reviewed for multiple performance obligations. Performance obligations can include amounts related to initial non-refundable license fees for the use of the Company's products and protocols and additional royalties on covered services. The Company granted license and sub-license agreements for various regions or States in the United States allowing the licensee to market, distribute and sell solely in the defined license territory, as defined, the products provided by the Company. The agreements are granted for a defined period or perpetual and are effective as long as annual milestones are achieved. Terms for payments for licensee agreements vary from full cash payment to defined terms. In cases where license or sub-license fees are uncollected or deferred; the Company nets those uncollected fees with the deferred revenue for balance sheet presentation. The Company amortizes license fees over the shorter of the economic life of the related contract life or contract terms for each licensee. On October 1, 2019, the Company launched the UnCraveRx™ Weight Loss Management Program. Customers are charged a membership fee and are requested to pay for three training programs at inception. The payment are recorded as deferred revenue until earned. The following table presents the changes in deferred revenue, reflected as current and long term liabilities on the Company's consolidated balance sheet: Balance as of December 31, 2018: Short term $ 209,474 Long term 207,523 Total as of December 31, 2018 416,997 Cash payments received 32,349 Net sales recognized (211,109 ) Balance as of December 31, 2019 238,237 Less short term 134,924 Long term $ 103,313 During the year ended December 31, 2019, the Company also had $29,150 in its revenues related to access fees, which were not included in deferred revenue. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of stock-based compensation, the fair value of other equity and debt instruments, fair value of intangible assets, useful lives of assets and allowance for doubtful accounts. Accounts Receivable Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off against the allowance upon management's determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was $0 and $12,500 as of December 31, 2019 and 2018, respectively. Fair Value of Financial Instruments Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2019 and 2018. The respective carrying value of certain financial instruments approximated their fair values. These financial instruments include cash, accounts receivable, accounts payable, other receivable, and accrued expenses, and notes payable. The fair value of the Company's convertible notes payable is based on management estimates and reasonably approximates their book value. The fair value of lease liability is based on the present value of future lease payments at a discount rate of 8% over the lease term. The fair value of royalty obligation is calculated by the Probability Weighted Expected Return Model, which projects various scenarios of future treatment sales, and then calculates the associated payment value of the royalty. The carrying value of lease liability and royalty obligation on the consolidated balance sheet approximates their fair value. See Note 13 and 14 for stock based compensation and other equity instruments. Segment Information Accounting Standards Codification subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's principal operating segment. Long-Lived Assets The Company follows a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of the assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. No impairments was recognized for the year ended December 31, 2019 and 2018. Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. $0 and $250,000 impairment was recognized for the year ended December 31, 2019 and 2018, respectively. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset's estimated useful life of 5 to 15 years. Expenditures for maintenance and repairs are expensed as incurred. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. Leases The Company determines if an arrangement is a lease at inception. Operating lease right-of-use assets ("ROU assets") and short-term and long-term lease liabilities are included on the face of the consolidated balance sheet. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component. For lease agreements with terms less than 12 months, the Company has elected the short-term lease measurement and recognition exemption, and it recognizes such lease payments on a straight-line basis over the lease term. Net (loss) Per Share The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"), which requires presentation of basic and diluted earnings per share ("EPS") on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares. The effect of common stock equivalents is anti-dilutive with respect to losses and therefore basic and dilutive is the same. Diluted net loss per share is calculated by including any potentially dilutive share issuances in the denominator. The following securities are excluded from the calculation of weighted average diluted shares at December 31, 2019 and 2018, respectively, because their inclusion would have been anti-dilutive. 2019 2018 Shares underlying options outstanding 822,797 791,850 Shares underlying warrants outstanding 72,500 85,250 Shares underlying convertible notes outstanding - 1,312,500 Convertible preferred stock outstanding 240,000 240,000 1,135,297 2,429,600 Advertising The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $436,205 and $88,912 as advertising costs for the years ended December 31, 2019 and 2018, respectively. Grant Income On January 17, 2019, the Company received a Notice of Award from the United States Department of Health and Human Services for a grant from the National Institutes of Health ("NIH") in support of BICX102 from the National Institute on Drug Abuse. The grant provides for (i) $2,842,430 in funding during the first year and (ii) $2,831,838 during the second year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds. Grant payments received prior to the Company's performance of work required by the terms of the research grant are recorded as deferred income and recognized as grant income once work is performed and qualifying costs are incurred. As of December 31, 2019, $932,745 in grant funds were received and $1,091,061 were recorded as grant income. Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,125,098 and $151,768 for the years ended December 31, 2019 and 2018, respectively. Stock Based Compensation Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees at the grant date using the stock price observed in the trading market (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2019 and 2018, the Company has not recorded any unrecognized tax benefits. Royalty Obligations, net The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the effective interest method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation and the gross projected future payments was $7,171,200 and was recorded as non-cash interest expense over the life of the liability and offset to additional paid in capital at inception. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on total assets, equity, and net loss. Adjustments have been made to the consolidated balance sheets to reclassify $125,000 from third party notes payable to related party notes payable and $21,480 from related party notes payable to third party notes payable. Application of New Accounting Standards On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right to use assets of $25,465, lease liability of $26,229 and eliminated deferred rent of $764. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the 'package of practical expedients', which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. In determining the length of the lease term to its long term lease, the Company determined there was no embedded extension option. At lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company's estimated incremental borrowing rate of 8%. In July 2017 the FASB issued a two-part ASU 2017-11, “(Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception.” For public business entities the amendments in Part I of ASU 2017-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. On January 1, 2018, the Company adopted ASU 2017-11 by electing the retrospective method to the outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the fiscal year. Accordingly, the Company reclassified the fair value of the reset provisions embedded in previously issued warrants with embedded anti-dilutive provisions from liability to equity (accumulated deficit) in aggregate of $175,975. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows. |
GOING CONCERN AND MANAGEMENT'S
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS | 12 Months Ended |
Dec. 31, 2019 | |
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS | |
Note 3 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS | As of December 31, 2019, the Company had cash of $2,645,852 and working capital of $495,682. During the year ended December 31, 2019, the Company used net cash in operating activities of $2,937,127. The Company has not yet generated any significant revenues, and has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued. During the year ended December 31, 2019, the Company raised $100,000 in proceeds from the sale of common stock and $6,000,000 in proceeds in connection with subscription and royalty agreement (Note 12). The Company believes that its current cash on hand will not be sufficient to fund its projected operating requirements for the next twelve months following the filing of this report. The Company's primary source of operating funds since inception has been from proceeds from private placements of convertible and other debt and the sale of common stock. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. |
PREPAID EXPENSES
PREPAID EXPENSES | 12 Months Ended |
Dec. 31, 2019 | |
PREPAID EXPENSES | |
Note 4 - PREPAID EXPENSES | The Company's prepaid expenses consisted of the following at December 31, 2019 and 2018: 2019 2018 Prepaid insurance $ 81,475 $ 27,083 Prepaid subscription services 127,208 4,375 Other prepaid expenses 4,600 - $ 213,283 $ 31,458 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2019 | |
PROPERTY AND EQUIPMENT | |
Note 5 - PROPERTY AND EQUIPMENT | The Company's property and equipment consisted of the following at December 31, 2019 and 2018: 2019 2018 Office equipment $ 43,503 $ 34,234 Computer equipment 5,544 5,544 Manufacturing equipment 98,373 30,747 Leasehold improvement 35,888 - 183,308 70,525 Less accumulated depreciation (35,008 ) (26,156 ) $ 148,300 $ 44,369 Depreciation expense charged to operations amounted to $15,959 and $5,390, respectively, for the year ended December 31, 2019 and 2018, respectively. In July 2019 and August 2019, the Company disposed of part of its office equipment for a total consideration of $800, realizing a loss on sale of fixed assets of $1,902. |
LEASES
LEASES | 12 Months Ended |
Dec. 31, 2019 | |
LEASES | |
Note 6 - LEASE | Operating leases On March 9, 2016, the Company entered into a lease amendment and expansion agreement, whereby the Company agreed to lease office space in Anaheim, California, commencing July 1, 2016 and expiring on June 30, 2019. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right to use assets of $25,465, lease liability of $26,229 and eliminated deferred rent of $764. On February 14, 2019, the Company extended the term of its lease for an additional 63 months beginning July 1, 2019 (at expiry of the original lease). The extended term expires on September 30, 2024. The extended lease has escalating payments from $5,522 per month to $6,552 per month. On February 14, 2019, the Company reassessed the value of right to use assets and lease liability of $299,070. On July 15, 2019, the Company and its landlord agreed that the Company would move to a larger space within the building that currently houses its principal executive offices. The Company extended the term of its lease for an additional 63 months beginning November 1, 2019. The extended term expires on January 31, 2025. The extended lease has escalating payments from $9,505 per month to $11,018 per month. On November 1, 2019, the Company accounted for the modification as a separate lease contract and recorded right to use assets and lease liability of $201,263. During year ended December 31, 2019, the Company recorded $78,034 as lease expense to current period operations. Lease liability is summarized below: December 31, 2019 Total lease liability $ 505,139 Less: short term portion 76,977 Long term portion $ 428,162 Maturity analysis under these lease agreements are as follows: 2020 $ 114,625 2021 118,065 2022 121,606 2023 125,255 2024 and beyond 140,030 Less: Present value discount (114,442 ) Lease liability $ 505,139 Lease expense for the year ended December 31, 2019 was comprised of the following: Operating lease expense $ 78,034 Short-term lease expense - Variable lease expense - $ 78,034 During the year ended December 31, 2019, the Company paid $32,367 lease expense in cash. Weighted-average remaining lease term and discount rate for operating leases are as follows: Weighted-average remaining lease term 4.90 Weighted-average discount rate 8 % During the year ended December 31, 2018, rent expense was $52,029. As of December 31, 2018, future minimum lease payments for office space are as follows: Year ended December 31, 2019 $ 26,844 |
INTELLECTUAL PROPERTY LICENSING
INTELLECTUAL PROPERTY LICENSING RIGHTS | 12 Months Ended |
Dec. 31, 2019 | |
INTELLECTUAL PROPERTY LICENSING RIGHTS | |
Note 7 - INTELLECTUAL PROPERTY/ LICENSING RIGHTS | On August 20, 2018, the Company purchased all the worldwide rights of Naltrexone Implants formula(s) with exception of New Zealand and Australia from Trinity Compound Solutions, Inc for $10,000 and 20,000 shares of its common stock for an aggregate purchase price of $236,000. The Company started to amortize the intellectual property corresponding to the launch of the UnCraveRx Weight Loss Management Program in October 2019, and recorded $11,990 amortization expense during the year ended December 31, 2019. Amortization is computed on straight-line method based on estimated useful lives of 5 years. As of December 31, 2019, the accumulated amortization of the intellectual property was $11,990. The future amortization of the intellectual property are as follows: Year Amount 2020 $ 47,160 2021 47,160 2022 47,160 2023 47,160 2024 35,370 $ 224,010 On October 12, 2018 the Company's majority owned subsidiary, BioCorRx Pharmaceuticals Inc. acquired six patent families for sustained delivery platforms for the local delivery of biologic and small molecule drugs for an aggregate purchase price of $15,200. Amortization is computed on straight-line method based on estimated useful lives of 13 years. During the year ended December 31, 2019, the Company recorded amortization expense of $1,464. As of December 31, 2019, the accumulated amortization of these patents was $1,464. The future amortization of the patents are as follows: Year Amount 2020 $ 1,172 2021 1,169 2022 1,169 2023 1,169 2024 and after 9,057 $ 13,736 |
ACCOUNTS PAYABLE AND ACCRUED EX
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 12 Months Ended |
Dec. 31, 2019 | |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | |
Note 8 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES | Accounts payable and accrued expenses consisted of the following as of December 31, 2019 and 2018: 2019 2018 Accounts payable $ 709,353 $ 655,654 Interest payable on notes payable 1,138,157 802,114 Interest payable on notes payable, related parties 125,903 96,120 Deferred insurance 53,967 - Deferred rent - 764 $ 2,027,380 $ 1,554,652 |
NOTES PAYABLE
NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2019 | |
NOTES PAYABLE | |
Note 9 - NOTES PAYABLE | On January 26, 2018, the Company issued one unsecured promissory notes of $125,000 bearing interest at 8% per annum with both principal and initially interest due July 26, 2018. In connection with the note issuance, the Company issued 50,000 shares of the Company's common stock to the note holder. The fair value of the common stock at the date of issuance of $12,750 was recorded as a debt discount and is amortized as interest expense over the term of the note. On July 26, 2018, the Company issued 100,000 shares in connection with extending the notes until December 26, 2018, the fair value of the common stock of $12,000 was charged to current period interest. On January 26, 2019, the Company paid $10,000 interest and issued 1,000 shares of its common stock valued at $7,500 to extend the note until September 26, 2019. On September 23, 2019, the Company paid the note in full. On November 15, 2018 and December 12, 2018, the Company issued two promissory notes for $275,000 each (aggregate of $550,000) for net proceeds of $250,000 each, after an original interest discount ("OID") of $25,000 each. The notes are due nine months from the date of issuance and bear a charge of 8% interest applied at issuance date and due upon maturity. In addition, the Company issued 2,500 shares of common stock and 5,000 warrants to acquire the Company's common stock at $20.00 expiring three years from the date of issuance per each note. The fair value of the common stock, warrants and together with the OID in aggregate of $144,661 was recorded as a debt discount and is amortized over the term of the notes. The fair value of the warrants was determined using the Black-Scholes option method with the following assumptions: expected life 3 years, volatility: 176.31% to 177.01%, risk free rate: 2.78% to 2.91% and stock price: $7.20 to $7.30. On April 26, 2019, the Company paid in full one of the promissory notes, including accrued interest of $22,000. On July 9, 2019, the Company paid the second promissory note in full. As of December 31, 2019 and 2018, the Company had advances from a third party. The advances bears no interest and is due on demand. The balance outstanding as of December 31, 2019 and 2018 was $21,480. During the year ended December 31, 2019 and 2018, the Company amortized $127,419 and $17,242, respectively, of the debt discount to current period interest expense. The interest expense during the year ended December 31, 2019 and 2018 were $8,110 and $53,288, respectively. |
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2019 | |
CONVERTIBLE NOTES PAYABLE | |
Note 10 - CONVERTIBLE NOTES PAYABLE | On June 10, 2016, the Company issued to BICX Holding Company, LLC a $2,500,000 senior secured convertible promissory note due March 3, 2020 and bearing interest at 8% per annum due annually beginning June 10, 2018. On March 3, 2017 the convertible promissory note was subsequently amended and was convertible into 42.43% of the Company's total authorized common stock. The Company also received an additional investment of $1,660,000 from the holder. The note was convertible into a fixed number of shares of common stock equal to 42.43% (2,227,575 shares) of the total authorized common stock as of March 3, 2017 (closing). On September 30, 2019, the convertible promissory note was converted to 2,227,575 shares of the Company s common stock, and the principal balance of the convertible note payable was reduced to $0. Upon converting the convertible note payable to common stock in September 2019, the Company and BICX Holding Company, LLC entered into a conversion agreement in which future interest through March 2020 on the convertible note payable was accelerated, and the Company agreed to pay $1,138,157 in interest within a twelve month period of an intended public offering. The interest is recorded in Accounts payable and accrued expenses on the consolidated balance sheet at December 31, 2019. In connection with the conversion agreement, the Company and BICX Holding Company, LLC entered into a Lock-Up Agreement (the Lock-Up Agreement ) pursuant to which the Investor will not sell, or otherwise dispose of the Conversion Shares, during the period commencing on October 1, 2019 and ending six (6) months following the initial closing of the Company s intended public offering of its securities to raise gross proceeds to the Company of at least $10,000,000 (subject to adjustment in the Company s sole discretion) (the Public Offering ). In the event that the intended public offering is terminated or abandoned prior to closing then the lock-up shall expire upon the later of the date which is six (6) months from September 30, 2019 or thirty (30) days from the date of such termination or abandonment. In accordance with the conversion agreement, the Company cannot enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents at an issuance price below $2.00 per share. During the year ended December 31, 2019 and 2018, the Company amortized $656,231 and $1,487,728 of the debt discount to current period interest expense. The interest expense during the year ended December 31, 2019 and 2018 were $389,330 and $332,800 and includes the accelerated interest noted above. |
NOTES PAYABLE-RELATED PARTIES
NOTES PAYABLE-RELATED PARTIES | 12 Months Ended |
Dec. 31, 2019 | |
NOTES PAYABLE-RELATED PARTIES | |
Note 11 - NOTES PAYABLE-RELATED PARTIES | As of December 31, 2019 and 2018, the Company had advances from Kent Emry (Chairman of the Company). The balance outstanding as of December 31, 2019 and 2018 was $1,500. On January 26, 2018, the Company issued to Joe Galligan (majority shareholder of the Company) one unsecured promissory notes of $125,000 bearing interest at 8% per annum with both principal and initially interest due July 26, 2018. In connection with the note issuance, the Company issued 50,000 shares of the Company's common stock to Joe Galligan. The fair value of the common stock at the date of issuance of $12,750 was recorded as a debt discount and is amortized as interest expense over the term of the note. On January 26, 2019, the note was extended until September 26, 2019. On September 23, 2019, the note was extended until September 26, 2020. On December 31, 2019, the note was extended until December 31, 2020. The balance outstanding as of December 31, 2019 and 2018 was $125,000. On January 22, 2013, the Company issued an unsecured promissory note payable to Kent Emry (Chairman of the Company) for $200,000 due January 1, 2018, with a stated interest rate of 12% per annum beginning three months from issuance, payable monthly. Principal payments were due starting February 1, 2015 at $6,650 per month. The lender has an option to convert the note to licensing rights for the State of Oregon. The Company currently is in default of the principal and interest. The note holder subsequently became an officer of the Company. The balance outstanding as of December 31, 2019 and 2018 was $163,610. The interest expense during the year ended December 31, 2019 and 2018 were $29,783 and $29,071, respectively. As of December 31, 2019 and 2018, the accumulated interest on related parties notes payable were $125,903 and $96,120, respectively. |
ROYALTY OBLIGATIONS, NET
ROYALTY OBLIGATIONS, NET | 12 Months Ended |
Dec. 31, 2019 | |
ROYALTY OBLIGATIONS, NET | |
Note 12 - ROYALTY OBLIGATION,NET | In March 2019, the Company entered into two Subscription and Royalty Agreements (the "Subscription and Royalty Agreements"). One was with Louis and Carolyn Lucido CRT LLC, managed by Mr. Louis Lucido, a member of the Company's Board of Directors (the "Board"), and the other one was with the J and R Galligan Revocable Trust, managed by Mr. Joseph Galligan, a majority shareholder of the Company. Pursuant to the Subscription and Royalty Agreements: (i) Each party would purchase shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the "Purchase Price"), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the "Initial Sales Date") and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the "Royalty"). Under the Lucido agreement, the Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company's weight loss program (the "Business") including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. As of December 31, 2019, the Company is in compliance with the use of proceeds requirement. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development. Under the second agreement, the Company will have complete discretion as to the exact amount of the aggregate purchase price to be allocated to the development and expansion of the Business. The Company accounted for this transaction as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the effective interest method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation and the gross projected future payments was $7,171,200 and was recorded as non-cash interest expense over the life of the liability and offset to additional paid in capital at inception. During the year ended December 31, 2019, the Company amortized $358,882 as interest expense. |
STOCKHOLDERS' EQUITY (DEFICIT)
STOCKHOLDERS' EQUITY (DEFICIT) | 12 Months Ended |
Dec. 31, 2019 | |
STOCKHOLDERS' EQUITY (DEFICIT) | |
Note 13 - STOCKHOLDERS' EQUITY/(DEFICIT) | Effective January 22, 2019, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 100 shares of common stock. As a result, 259,984,655 shares of the Company's common stock were exchanged for 2,599,847 shares of the Company's common stock. These consolidated financial statements have been retroactively restated to reflect the reverse stock split. Convertible Preferred stock The Company is authorized to issue 600,000 shares of preferred stock with no par value. As of December 31, 2019 and 2018, the Company had 80,000 shares of Series A preferred stock and 160,000 shares of Series B preferred stock issued and outstanding. As of December 31, 2019 and 2018 each share of Series A preferred stock is entitled to one thousand (1,000) votes and is convertible into one share of common stock. 30,000 shares of Series A Preferred Stock are owned by management. The Series A Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series A. Each share of Series A Preferred Stock may be converted, at the option of the holder each share of Series A Preferred Stock may be converted equal to one (1) fully paid and nonassessable share of Common Stock, par value $0.001. As of December 31, 2019 and 2018 each share of Series B stock is entitled to two thousand (2,000) votes and is convertible into one share of common stock. 120,000 shares of Series B Preferred Stock are owned by management. The Series B Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series B. Each share of Series B Preferred Stock may be converted, at the option of the holder each share of Series B Preferred Stock may be converted equal to one (1) fully paid and nonassessable share of Common Stock, par value $0.001. Common stock On May 10, 2018, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada increasing the total number of shares which the Company is authorized to issue from five hundred twenty five million six hundred thousand (525,600,000) shares to seven hundred fifty million six hundred thousand (750,600,000) shares and increasing the number of authorized shares of common stock from five hundred and twenty five million (525,000,000) shares of common stock, $0.001 par value, to seven hundred and fifty million (750,000,000) shares of common stock. Year ended December 31, 2018 During the year ended December 31, 2018, the Company issued an aggregate of 40,248 shares of its common stock for services rendered valued at $457,730 based on the underlying market value of the common stock at the date of issuance. During the year ended December 31, 2018, the Company issued 10,000 shares of its common stock in connection with a distribution agreement previously accrued during the year ended December 31, 2017. During the year ended December 31, 2018, the Company issued an aggregate of 6,000 shares of its common stock in connection with the issuance of promissory notes payable valued at $61,750 based on the underlying market value of the common stock at the date of issuance. During the year ended December 31, 2018, the Company issued 75,000 shares of its common stock in exchange for proceeds of $1,400,000. Of this amount: (1) the Company issued 57,500 units of the Company s securities at a price per unit of $20 for total proceeds of $1,150,000 with each unit consisting of one share of the Company s common stock and a three-year warrant to purchase one share of the Company s Common Stock at an exercise price of $100 per share; (2) the Company issued 12,500 shares of its common stock at a price per share of $12 for proceeds of $150,000; and (3) the Company issued 5,000 shares of its common stock at a price per share of $20 for proceeds of $100,000. During the year ended December 31, 2018, the Company issued an aggregate of 1,000 shares of its common stock in connection with the extension of promissory notes payable valued at $12,000 based on the underlying market value of the common stock at the date of issuance. During the year ended December 31, 2018, the Company issued an aggregate of 4,236 shares of its common stock to settle its outstanding accounts payable valued at $29,653 based on the underlying market value of the common stock at the date of issuance. During the year ended December 31, 2018, the Company purchased all the worldwide rights of Naltrexone Implants formula(s) with exception of New Zealand and Australia from Trinity Compound Solutions, Inc for $10,000 and 20,000 shares of its common stock for an aggregate purchase price of $236,000. Year ended December 31, 2019 During the year ended December 31, 2019, the Company issued an aggregate of 75,017 shares of its common stock for services rendered valued at $271,050 based on the underlying market value of the common stock at the date of issuance, among which 29,111 shares valued at $100,000 were issued to the board of directors for board compensation. During the year ended December 31, 2019, the Company issued 3,842 shares of its common stock to pay for interest expense valued at $21,000 based on the underlying market value of the common stock at the date of issuance. In January 2019, the Company issued 849 round-up shares for the Reverse Stock Split. In February 2019, the Company issued 22,222 shares of its common stock valued at $100,000 in connection with the February 2019 common stock subscription. In March 2019, the Company issued an aggregate of 400,000 shares of its common stock under proceeds related to the Subscription and Royalty Agreements. Subsequently in April 2019, the Company received the proceeds of $6,000,000. In September 2019, the Company issued an aggregate of 2,227,575 shares of its common stock to convert the convertible note with an amount of $4,160,000. |
STOCK OPTIONS AND WARRANTS
STOCK OPTIONS AND WARRANTS | 12 Months Ended |
Dec. 31, 2019 | |
STOCK OPTIONS AND WARRANTS | |
Note 14 - STOCK OPTIONS AND WARRANTS | Options On November 13, 2014, our Board of Directors authorized and approved the adoption of the Plan effective November 13, 2014 (2014 Stock Option Plan) under which an aggregate of 20% (290,879 shares) of the issued and outstanding shares may be issued. The plan shall terminate ten years after the plan's adoption by the board of directors. We granted an aggregate 145,000 stock options. As of December 31, 2019, an aggregate total of 145,879 can still be granted under the plan. On June 15, 2016, our board of Directors authorized and approved the adoption of the Equity Incentive Plan effective June 15, 2016 (2016 Equity Incentive Plan) under which an aggregate of 656,250 shares may be issued. The plan shall terminate ten years after the plan's adoption by the board of directors. We granted an aggregate of 330,350 stock options. As of December 31, 2019, an aggregate total of 325,900 options can still be granted under the plan. On May 15, 2018, the Board of Directors approved and adopted the BioCorRx Inc. 2018 Equity Incentive Plan (2018 Stock Option Plan) under which an aggregate of 450,000 shares may be issued. The plan shall terminate ten years after the plan's adoption by the board of directors. The company has granted an aggregate of 347,447 stock options. As of December 31, 2019, an aggregate total of 102,553 can still be granted under the plan. During the year ended December 31, 2019, the Board of Directors approved the grant of 53,280 stock options to consultants valued at $233,111. The term of the options ranges from one to five years, and the vesting period of the options ranges from one to two years. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from using the Company's historical stock prices. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the "simplified" method, which is used for "plain-vanilla" options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. In applying the Black-Scholes option pricing model, the Company used the following assumptions: 2019 2018 Risk-free interest rate 2.36% - 2.58% 2.85 % Expected term (years) 1.00 5.00 5.50 Expected volatility 99.85% - 143.11% 135.18 % Expected dividends 0.00 0.00 The following table summarizes the stock option activity for the year ended December 31, 2019 and 2018: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2018 478,850 $ 4.00 8.9 $ 326,700 Grants 315,000 14.00 5.0 - Exercised - - - - Expired (2,000 ) 10.00 - - Outstanding at December 31, 2018 791,850 8.09 7.7 1,188,065 Grants 53,280 6.52 2.5 - Exercised - - - - Expired (1,500 ) 20.00 - - Forfeited (20,833 ) 5.75 - - Outstanding at December 31, 2019 822,797 $ 8.03 6.5 $ 244,603 Exercisable at December 31, 2019 814,607 $ 8.04 6.6 $ 244,603 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company's stock price of $2.75 as of December 31, 2019, which would have been received by the option holders had those option holders exercised their options as of that date. The following table presents information related to stock options at December 31, 2019: Options Outstanding Options Exercisable Weighted Weighted Average Exercisable Average Exercise Number of Remaining Life Number of Remaining Life Price Options In Years Options In Years $0.01-2.50 330,350 6.5 330,350 6.5 2.51-5.00 35,000 0.6 35,000 0.6 5.01 and up 457,447 7.0 449,257 7.1 822,797 6.5 814,607 6.6 The stock-based compensation expense related to option grants was $1,694,653 and $2,349,427 during the year end December 31, 2019 and 2018, respectively. As of December 31, 2019, stock-based compensation related to options of $26,999 remains unamortized and is expected to be amortized over the weighted average remaining period of 10.6 months. Warrants The outstanding Warrants contain provisions, often referred to as down-round protection that has led to adjustments of the exercise price and number of underlying warrant shares with respect to future issuances by the Company of its securities, including its common stock or convertible securities or debt securities. On January 1, 2018, the Company adopted ASU 2017-11 by electing the retrospective method to the outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the fiscal year. Accordingly, the Company reclassified the fair value of the reset provisions embedded in previously issued warrants with embedded anti-dilutive provisions from liability to equity (accumulated deficit) in aggregate of $175,975. The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company's common stock: Warrants Outstanding Warrants Exercisable Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (Years) $ 20.00 10,000 1.91 $ 20 10,000 1.91 100.00 62,500 1.39 100 62,500 1.39 72,500 1.46 $ 89.0 72,500 1.46 The following table summarizes the warrant activity for the year ended December 31, 2019: Number of Shares Weighted Average Exercise Price Per Share Outstanding at January 1, 2018 24,300 $ 91.00 Issued 72,500 88.97 Exercised - - Expired (11,550 ) 100.00 Outstanding at December 31, 2018 85,250 $ 79.40 Issued - - Exercised - - Expired (12,750 ) 25.00 Outstanding at December 31, 2019 72,500 $ 89.00 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2019 | |
RELATED PARTY TRANSACTIONS | |
Note 15 - RELATED PARTY TRANSACTIONS | The Company has an arrangement with Premier Aftercare Recovery Service, ("PARS"). PARS is a Company controlled by Neil Muller, a shareholder of the Company and prior officer of the Company, that provided consulting services to the Company. There is no formal agreement between the parties and the amount of remuneration was $14,583 per month. During year ended December 31, 2019 and 2018, the Company incurred $0 as consulting fees and expense reimbursements. As of December 31, 2019 and 2018, there was an unpaid balance of $0 and $32,318, respectively. The Company has an arrangement with Felix Financial Enterprises ("FFE"). FFE is a Company controlled by Lourdes Felix, an officer of the Company that provides consulting services to the Company. Until June 13, 2018, there was no formal agreement between the parties and the amount of remuneration is $14,583 per month. For the year ended December 31, 2019 and 2018, the Company incurred $250,000 and $200,625, respectively, as consulting fees and bonuses. The agreement provides for a base salary of $175,000 an auto allowance and mobile phone stipend. As of March 27, 2020 the Company will pay Ms. Lourdes Felix an annual base salary of $190,000 in place of consulting fees and will be paid in accordance with the Company’s normal payroll schedule. Executive’s base salary shall be subject to review by the Board of Directors. The Company has an arrangement with Soupface LLC ("Soupface"). Soupface is a Company controlled by Brady Granier, an officer of the Company that provides consulting services to the Company. Until June 13, 2018, there was no formal agreement between the parties and the amount of remuneration is $15,833 per month. For the year ended December 31, 2019 and 2018, the Company incurred $265,000 and $212,500, respectively, as consulting fees and bonuses. The agreement provides for a base salary of $190,000 an auto allowance and mobile phone stipend. As of March 27, 2020 the Company will pay Mr. Brady Granier an annual base salary of $215,000 in place of consulting fees and will be paid in accordance with the Company’s normal payroll schedule. Executive’s base salary shall be subject to review by the Board of Directors. The Company has an arrangement with Mr. Tom Welch, VP of Operations. Until June 13, 2018 there was no formal agreement between the parties and the amount of remuneration is $12,500 per month. For the year ended December 31, 2019 and 2018, the Company incurred $150,000 and $167,417, respectively, as consulting fees and bonuses.The agreement provides for a base salary of $150,000 an auto allowance and mobile phone stipend. As of March 27, 2020 the Company will pay Mr. Tom Welch an annual base salary of $175,000 in place of consulting fees and will be paid in accordance with the Company’s normal payroll schedule. Executive’s base salary shall be subject to review by the Board of Directors. The Company has an arrangement with Joseph Galligan, a majority shareholder of the Company, related to his compensation for his role as a senior advisor. Until January 22, 2019 there was no formal arrangement between the parties and the amount of renumeration is $6,250 per month. For the year ended December 31, 2019 and 2018, the Company incurred $68,750 and $-0-, respectively, as consulting fees. On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc. for the purpose of developing certain business lines. In connection with the formation, the newly formed sub issued 24.2% ownership to current or former officers of the Company, with the Company retaining 75.8%. In 2018, BioCorRx Pharmaceuticals, Inc. began limited operations and there was no operation prior to that. In March 2019, the Company entered into two Subscription and Royalty Agreements (the "Subscription and Royalty Agreements"). One was with Louis and Carolyn Lucido CRT LLC, managed by Mr. Louis Lucido, a member of the Company's Board of Directors (the "Board"), and the other one was with the J and R Galligan Revocable Trust, managed by Mr. Joseph Galligan, a majority shareholder of the Company. The Company received an aggregate gross proceeds of $6,000,000 in April 2019 and $210 royalty was due at December 31, 2019 under these two Subscription and Rotalty Agreements. As of December 31, 2019 and 2018, the Company's’ related party payable was $391,209 and $32,318 respectively, which comprised of compensation payable and interest payable to related parties. Effective March 1, 2019, the Board appointed five directors. In connection with the appointment to the Board, the Company entered into a Director Agreement with each directors pursuant to which each of them will receive a quarterly cash stipend of $15,000 in compensation for services and shall be issued, upon the last day of each fiscal quarter, provided the director is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000. During the year ended December 31, 2019, the Company issued 29,111 shares of common stock valued at $100,000 to directors. |
CONCENTRATIONS
CONCENTRATIONS | 12 Months Ended |
Dec. 31, 2019 | |
CONCENTRATIONS | |
Note 16 - CONCENTRATIONS | Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. The Company's revenues earned from sale of products and services for the year ended December 31, 2019 included 33%, 21%, 17%, and 15% (aggregate of 86%) from four customers of the Company's total revenues. The Company's revenues earned from sale of products and services for the year ended December 31, 2018 included 13%, 18%, 22%, and 20% (aggregate of 73%) from four customers of the Company's total revenues. At December 31, 2019, one customer accounted for 100% of the Company s total accounts receivable with an amount of $750, and three customers accounted for 44%, 17% and 32% (aggregate of 93%) of the Company's total accounts receivable at December 31, 2018. |
NON CONTROLLING INTEREST
NON CONTROLLING INTEREST | 12 Months Ended |
Dec. 31, 2019 | |
NON CONTROLLING INTEREST | |
Note 17 - NON CONTROLLING INTEREST | On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the, the newly formed sub issued 24.2% ownership to current or former officers of the Company with the Company retaining 75.8%. From inception through December 31, 2017, there were no significant transactions. There were certain licensing rights with a carrying value of $250,000 and no significant liabilities in BioCorRx Pharmaceuticals, Inc. In 2018, BioCorRx Pharmaceuticals, Inc. began operations. A reconciliation of the BioCorRx Pharmaceuticals, Inc. non-controlling loss attributable to the Company: Net loss attributable to the non-controlling interest for the year ended December 31, 2019: Net loss $ (35,914 ) Average Non-controlling interest percentage of profit/losses 24.2 % Net loss attributable to the non-controlling interest $ (8,691 ) Net loss attributable to the non-controlling interest for the year ended December 31, 2018: Net loss $ (299,533 ) Average Non-controlling interest percentage of profit/losses 24.2 % Net loss attributable to the non-controlling interest $ (72,487 ) The following table summarizes the changes in non-controlling interest for the year ended December 31, 2019: Balance, December 31, 2018 $ (72,487 ) Net loss attributable to the non-controlling interest (8,691 ) Balance, December 31, 2019 (81,178 ) The following table summarizes the changes in non-controlling interest for the year ended December 31, 2018: Balance, December 31, 2017 - Net loss attributable to the non-controlling interest (72,487 ) Balance, December 31, 2018 $ (72,487 ) |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2019 | |
COMMITMENTS AND CONTINGENCIES | |
Note 18 - COMMITMENTS AND CONTINGENCIES | Lucido Subscription and Royalty Agreement On March 28, 2019, the Company entered into a Subscription and Royalty Agreement (the "Lucido Subscription and Royalty Agreement") with Louis and Carolyn Lucido CRT LLC, managed by Mr. Louis Lucido, a member of the Company's Board of Directors (the "Board"). Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the "Purchase Price"), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the "Initial Sales Date") and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the "Royalty"). The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company's weight loss program (the "Business") including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development. The Company issued 200,000 common shares to Lucido on March 28, 2019 and recorded the fair value of the shares in equity. The Company recorded a liability for the Royalty when the obligation began upon the receipt of proceeds in April 2019. Galligan Subscription and Royalty Agreement On April 1, 2019, the Company entered into a Subscription and Royalty Agreement (the "Galligan Subscription and Royalty Agreement" and, together with the Lucido Subscription and Royalty Agreement, the "Agreements") with the J and R Galligan Revocable Trust, managed by Mr. Joseph Galligan, a majority shareholder of the Company. Although the Galligan Subscription and Royalty Agreement was dated March 27, 2019, it did not become effective until it was fully executed on April 1, 2019. The terms and conditions of the Galligan Subscription and Royalty Agreement (including the amount of shares of Common Stock purchased, the Purchase Price, and the terms of the Royalty) are substantially the same as the Lucido Subscription and Royalty Agreement except that the Company will have complete discretion as to the exact amount of $3,000,000 of the Galligan Subscription and Royalty Agreement to be allocated to the development and expansion of the Business. The Company issued 200,000 common shares to Galligan on March 28, 2019 and recorded the fair value of the shares in equity. The Company recorded a liability for the Royalty when the obligation began upon the receipt of proceeds in April 2019. Alpine Creek Capital Partners LLC On December 10, 2015, the Company entered into a royalty agreement with Alpine Creek Capital Partners LLC ("Alpine Creek"). The Company is in the business of selling a distinct implementation of the BioCorRx Recovery Program, a two-tiered comprehensive MAT program, which includes a counseling program, coupled with its proprietary Naltrexone Implant (the "Treatment"). In consideration for the payment, with the exception of treatments conducted in certain territories, the Company will pay Alpine Creek fifty percent (50%) of the Company's gross profit for each Treatment sold in the United States that includes procurement of the Company's implant product until the Company has paid Alpine Creek $1,215,000. In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories. Upon the Company's satisfaction of these obligations, the Company shall pay Alpine Creek $100 for each treatment sold in the United States that includes procurement of the Company's implant product, into perpetuity. The amount of royalty due for the year ended December 31, 2019 is $3,503. As of December 31, 2019, $85,805 is owed to Alpine Creek, which was paid subsequently in January 2020. On any other proprietary implant distribution, that excludes the "treatment", for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company's gross profit for implant distribution not to exceed $100 per sale. As of December 31, 2019, there are no payments due. BICX Holding Company LLC Effective September 30, 2019, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with BICX Holding Company LLC (“BICX”), an entity controlled by Alpine Creek, pursuant to which the parties agreed to the conversion (the “Conversion”) of the Senior Secured Convertible Promissory Note in the principal amount of $4,160,000 (the “Note”), which was issued by the Company to the Investor on June 10, 2016, into 2,227,575 shares of the Company’s common stock (the “Conversion Shares”). In connection with the Conversion Agreement, the Company and BICX entered into a Lock-Up Agreement (the “Lock-Up Agreement”) pursuant to which the Investor will not sell, or otherwise dispose of the Conversion Shares, during the period commencing on October 1, 2019 and ending six (6) months following the initial closing of the Company’s intended public offering of its securities to raise gross proceeds to the Company of at least $10,000,000 (subject to adjustment in the Company’s sole discretion) (the “Public Offering”). In the event that the Public Offering is terminated or abandoned prior to closing then the lock-up shall expire upon the later of the date which is six (6) months from September 30, 2019 or thirty (30) days from the date of such termination or abandonment. In accordance with the Conversion Agreement, the Company cannot enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents at an issuance price below $2.00 per share. Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. Charles River Laboratories, Inc. On May 24, 2019, the Company entered into a Master Services Agreement (the "MSA") with Charles River Laboratories, Inc. ("Charles River"). Pursuant to the MSA, Charles River will be conducting studies with regard to BICX102. Studies will be conducted pursuant to Statements of Work entered into by the Company and Charles River. On May 30, 2019, the Company and Charles River entered into two separate Statements of Work pursuant to which Charles River is conducting a total of six studies. As of March 27, 2020 the Company will pay Charles River the total amended consideration of $3,024,476 for these six studies. For the year ended December 31, 2019, the Company incurred $382,915 as research and development expenses. The remaining total consideration the Company will pay Charles River is $2,641,561. Sinclair Research Center LLC On February 18, 2020, the Company entered into a Master Services Agreement (the "MSA") with Sinclair Research Center LLC ("Sinclair"). Pursuant to the MSA, Sinclair will be conducting studies with regard to BICX102. Studies will be conducted pursuant to Statements of Work entered into by the Company and Sinclair. On February 20, 2020 the Company and Sinclair entered into a Statement of Work pursuant to which Sinclair is conducting one study. The total consideration the Company will pay Sinclair for the study is $894,600. As of March 27, 2020, the Company incurred $357,840 as research and development expenses. Agreements As of December 31, 2019 the Company has entered into seven consulting and scientific advisory board agreements. In compensation for services: (i) two advisory board members shall be issued common stock equivalent to $5,000 the last day of such quarter when meetings are held; (ii) one consultant shall receive common stock equivalent to $6,250 on the last day of each month; (iii) one consultant shall receive a renumeration amount of $10,000-$12,500 per month with an earn out potential of 1% of the Company's majority owned subsidiary, BioCorRx Pharmaceuticals based on certain factors; (iv) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; and (v) one consultant shall receive common stock equivalent to $6,667 on the last day of each month (vi) one consultant shall receive a renumeration amount of $5,500 per month During 2019, the Company entered into a contract manufacturing agreement for an estimated total cost of $578,500 to be paid over time. For the year ended December 31, 2019, the Company incurred $234,852 as research and development expenses. The remaining total consideration is $343,648. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2019 | |
INCOME TAXES | |
Note 19 - Income Taxes | The components of the income tax provisions for 2019 and 2018 are as follows: 2019 2018 Current provision: Federal $ - $ - State - - Deferred benefit: Federal - - State - - - - Change in valuation allowance - - Total Provision $ - $ - The difference between the income tax provision and income taxes computed using the U. S. federal income tax rate of 21% consisted of the following: 2019 2018 Provision at statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 6.98 % 6.98 % Nondeductible and other items (0.07 )% (0.03 )% Change in valuation allowance (27.91 )% (27.95 )% Total (0.0 )% (0.0 )% Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred taxes as of December 31, 2019 and 2018 are as follows: 2019 2018 Deferred tax assets: Allowance for doubtful debt $ 7,598 $ 6,926 Stock options issued for services 1,632,377 1,082,303 Net operating loss carryforward 4,766,552 3,126,434 Other 19,516 560 Total deferred tax assets 6,426,043 4,216,223 Deferred tax liabilities: Royalty obligation (708,046 ) - Other (42,915 ) (229,598 ) Total deferred tax liabilities (750,961 ) (229,598 ) Deferred tax asset 5,675,082 3,986,625 Valuation allowance (5,675,082 ) (3,986,625 ) A full valuation allowance has been provided against the Company's deferred tax assets at December 31, 2019 as the Company believes it is more likely than not that sufficient taxable income will not be generated to realize these temporary differences. The Company has Federal net operating losses (NOLs) of approximately $17.0 million which begin to expire in the years beginning in 2033. Pursuant to Section 382 of the Internal Revenue Code, use of the Company's NOLs and credit carry forwards may be limited if the Company experiences a cumulative change in ownership of greater than 50% in a moving three-year period. The Company also has federal credits that begin to expire 2031 and state tax credits that may be carried forward indefinitely. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards as set forth in ASC Topic 740 Income Taxes, regarding accounting for uncertainty in income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. There are no unrecognized benefits related to uncertain tax positions as of December 31, 2019. The Company does not anticipate that there will be material change in the liability for unrecognized tax benefits within the next 12 months. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”). The Tax Act establishes new tax laws that affects 2018 and future years, including a reduction in the U.S. federal corporate income tax rate to 21%, effective January 1, 2018. Valuation allowance increased $1,688,457 during the year ended December 31, 2019. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2019 | |
SUBSEQUENT EVENTS | |
Note 20 - SUBSEQUENT EVENTS | In January 2020, the Company was awarded a second year of funding from the National Institute on Drug Abuse ( NIDA ) to support the development of a 3-month implantable depot pellet of naltrexone for the treatment of Opioid Use Disorder, which the Company refers to as BICX102. The second-year grant provides for $2,831,838 in funding subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds. As of February 28, 2020 the Company issued an aggregate of 12,905 shares of its common stock for consulting services and one employee valued at $35,776. In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2019 | |
SIGNIFICANT ACCOUNTING POLICIES (Policies) | |
Basis of Presentation | The consolidated financial statements include the accounts of BioCorRx Inc. and its wholly owned subsidiary, Fresh Start Private, Inc. and its majority owned subsidiary, BioCorRx Pharmaceuticals, Inc. (hereafter referred to as the "Company" or "BioCorRx"). All significant intercompany balances and transactions have been eliminated in consolidation. |
Revenue Recognition | The Company recognizes revenue in accordance with Financial Accounting Standards Board "FASB" Accounting Standards Codification "ASC" 606. A five-step analysis a must be met as outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. There were no changes to the Company's revenue recognition policy from the adoption of ASC 606. The Company has elected the following practical expedients in applying ASC 606: • Unsatisfied Performance Obligations - all performance obligations relate to contracts with a duration of less than one year. The Company has elected to apply the optional exemption provided in ASC 606 and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. • Contract Costs - all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. • Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component as the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. • Sales Tax Exclusion from the Transaction Price - the Company excludes from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer. • Shipping and Handling Activities - the Company elected to account for shipping and handling activities as a fulfillment cost rather than as a separate performance obligation. • Modified Retrospective Method - the Company adopted ASC 606 on January 1, 2018 utilizing the modified retrospective method allowing the Company to not retrospectively adjust prior periods. The Company applied the modified retrospective method only to contracts that were not completed at January 1, 2018 and accounted for the aggregate effect of any contract modifications upon adoption. The Company's net sales are disaggregated by product category. The sales/access fees consist of product sales, which is recognized upon the transfer of promised goods to customers. The distribution rights income consists of the income recognized from the amortization of distribution agreements entered into for its products. The membership/program fees are generated from the Company’s UnCraveRx™ Weight Loss Management Program, which is recognized upon the transfer of promised goods to customers. The following table presents our net sales by product category for the year ended December 31, 2019 and 2018: 2019 2018 Sales/access fees $ 29,150 $ 129,960 Distribution rights income 207,110 246,696 Membership/program fees 3,999 - Net sales $ 240,259 $ 376,656 |
Deferred revenue | The Company licenses proprietary products and protocols to customers under licensing agreements that allow those customers to access the products and protocols in services they provide to their customers during the term of the license agreement. The timing and amount of revenue recognized from license agreements depends upon a variety of factors, including the specific terms of each agreement. Such agreements are reviewed for multiple performance obligations. Performance obligations can include amounts related to initial non-refundable license fees for the use of the Company's products and protocols and additional royalties on covered services. The Company granted license and sub-license agreements for various regions or States in the United States allowing the licensee to market, distribute and sell solely in the defined license territory, as defined, the products provided by the Company. The agreements are granted for a defined period or perpetual and are effective as long as annual milestones are achieved. Terms for payments for licensee agreements vary from full cash payment to defined terms. In cases where license or sub-license fees are uncollected or deferred; the Company nets those uncollected fees with the deferred revenue for balance sheet presentation. The Company amortizes license fees over the shorter of the economic life of the related contract life or contract terms for each licensee. On October 1, 2019, the Company launched the UnCraveRx Weight Loss Management Program. Customers are charged a membership fee and are requested to pay for three training programs at inception. The payment are recorded as deferred revenue until earned. The following table presents the changes in deferred revenue, reflected as current and long term liabilities on the Company's consolidated balance sheet: Balance as of December 31, 2018: Short term $ 209,474 Long term 207,523 Total as of December 31, 2018 416,997 Cash payments received 32,349 Net sales recognized (211,109 ) Balance as of December 31, 2019 238,237 Less short term 134,924 Long term $ 103,313 During the year ended December 31, 2019, the Company also had $29,150 in its revenues related to access fees, which were not included in deferred revenu |
Use of Estimates | The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of stock-based compensation, the fair value of other equity and debt instruments, fair value of intangible assets, useful lives of assets and allowance for doubtful accounts. |
Accounts Receivable | Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off against the allowance upon management's determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was $0 and $12,500 as of December 31, 2019 and 2018, respectively. |
Fair Value of Financial Instruments | Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2019 and 2018. The respective carrying value of certain financial instruments approximated their fair values. These financial instruments include cash, accounts receivable, accounts payable, other receivable, and accrued expenses, and notes payable. The fair value of the Company's convertible notes payable is based on management estimates and reasonably approximates their book value. The fair value of lease liability is based on the present value of future lease payments at a discount rate of 8% over the lease term. The fair value of royalty obligation is calculated by the Probability Weighted Expected Return Model, which projects various scenarios of future treatment sales, and then calculates the associated payment value of the royalty. The carrying value of lease liability and royalty obligation on the consolidated balance sheet approximates their fair value. See Note 13 and 14 for stock based compensation and other equity instruments. |
Segment Information | Accounting Standards Codification subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's principal operating segment. |
Long-Lived Assets | The Company follows a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of the assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. No impairments was recognized for the year ended December 31, 2019 and 2018. |
Intangible Assets | Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. $0 and $250,000 impairment was recognized for the year ended December 31, 2019 and 2018, respectively. |
Property and Equipment | Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset's estimated useful life of 5 to 15 years. Expenditures for maintenance and repairs are expensed as incurred. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. |
Leases | The Company determines if an arrangement is a lease at inception. Operating lease right-of-use assets ("ROU assets") and short-term and long-term lease liabilities are included on the face of the consolidated balance sheet. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component. For lease agreements with terms less than 12 months, the Company has elected the short-term lease measurement and recognition exemption, and it recognizes such lease payments on a straight-line basis over the lease term. |
Net (loss) Per Share | The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"), which requires presentation of basic and diluted earnings per share ("EPS") on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares. The effect of common stock equivalents is anti-dilutive with respect to losses and therefore basic and dilutive is the same. Diluted net loss per share is calculated by including any potentially dilutive share issuances in the denominator. The following securities are excluded from the calculation of weighted average diluted shares at December 31, 2019 and 2018, respectively, because their inclusion would have been anti-dilutive. 2019 2018 Shares underlying options outstanding 822,797 791,850 Shares underlying warrants outstanding 72,500 85,250 Shares underlying convertible notes outstanding - 1,312,500 Convertible preferred stock outstanding 240,000 240,000 1,135,297 2,429,600 |
Advertising | The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $436,205 and $88,912 as advertising costs for the years ended December 31, 2019 and 2018, respectively. |
Grant Income | On January 17, 2019, the Company received a Notice of Award from the United States Department of Health and Human Services for a grant from the National Institutes of Health ("NIH") in support of BICX102 from the National Institute on Drug Abuse. The grant provides for (i) $2,842,430 in funding during the first year and (ii) $2,831,838 during the second year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds. Grant payments received prior to the Company's performance of work required by the terms of the research grant are recorded as deferred income and recognized as grant income once work is performed and qualifying costs are incurred. As of December 31, 2019, $932,745 in grant funds were received and $1,091,061 were recorded as grant income. |
Research and development costs | The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,125,098 and $151,768 for the years ended December 31, 2019 and 2018, respectively. |
Stock Based Compensation | Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the trading market (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. |
Income Taxes | Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2019 and 2018, the Company has not recorded any unrecognized tax benefits. |
Royality Obligations, net | The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the effective interest method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation and the gross projected future payments was $7,171,200 and was recorded as non-cash interest expense over the life of the liability and offset to additional paid in capital at inception. |
Reclassification of Prior Year Presentation | Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on total assets, equity, and net loss. Adjustments have been made to the consolidated balance sheets to reclassify $125,000 from third party notes payable to related party notes payable and $21,480 from related party notes payable to third party notes payable. |
Application of New Accounting Standards | On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right to use assets of $25,465, lease liability of $26,229 and eliminated deferred rent of $764. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the 'package of practical expedients', which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. In determining the length of the lease term to its long term lease, the Company determined there was no embedded extension option. At lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company's estimated incremental borrowing rate of 8%. In July 2017 the FASB issued a two-part ASU 2017-11, (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception. For public business entities the amendments in Part I of ASU 2017-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. On January 1, 2018, the Company adopted ASU 2017-11 by electing the retrospective method to the outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the fiscal year. Accordingly, the Company reclassified the fair value of the reset provisions embedded in previously issued warrants with embedded anti-dilutive provisions from liability to equity (accumulated deficit) in aggregate of $175,975. |
Recent Accounting Pronouncements | There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows. |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
SIGNIFICANT ACCOUNTING POLICIES (Tables) | |
Schedule of net sales | The following table presents our net sales by product category for the year ended December 31, 2019 and 2018: 2019 2018 Sales/access fees $ 29,150 $ 129,960 Distribution rights income 207,110 246,696 Membership/program fees 3,999 - Net sales $ 240,259 $ 376,656 |
Schedule of changes in deferred revenue | The following table presents the changes in deferred revenue, reflected as current and long term liabilities on the Company's consolidated balance sheet: Balance as of December 31, 2018: Short term $ 209,474 Long term 207,523 Total as of December 31, 2018 416,997 Cash payments received 32,349 Net sales recognized (211,109 ) Balance as of December 31, 2019 238,237 Less short term 134,924 Long term $ 103,313 |
Schedule of computations of weighted average shares outstanding | 2019 2018 Shares underlying options outstanding 822,797 791,850 Shares underlying warrants outstanding 72,500 85,250 Shares underlying convertible notes outstanding - 1,312,500 Convertible preferred stock outstanding 240,000 240,000 1,135,297 2,429,600 |
PREPAID EXPENSES (Tables)
PREPAID EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
PREPAID EXPENSES (Tables) | |
Schedule of prepaid expenses | The Company's prepaid expenses consisted of the following at December 31, 2019 and 2018: 2019 2018 Prepaid insurance $ 81,475 $ 27,083 Prepaid subscription services 127,208 4,375 Other prepaid expenses 4,600 - $ 213,283 $ 31,458 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
PROPERTY AND EQUIPMENT (Tables) | |
Schedule of property and equipment | The Company's property and equipment consisted of the following at December 31, 2019 and 2018: 2019 2018 Office equipment $ 43,503 $ 34,234 Computer equipment 5,544 5,544 Manufacturing equipment 98,373 30,747 Leasehold improvement 35,888 - 183,308 70,525 Less accumulated depreciation (35,008 ) (26,156 ) $ 148,300 $ 44,369 |
LEASES (Tables)
LEASES (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
LEASES (Tables) | |
Schedule of lease liability | Lease liability is summarized below: December 31, 2019 Total lease liability $ 505,139 Less: short term portion 76,977 Long term portion $ 428,162 |
Schedule of maturity analysis under lease agreements | Maturity analysis under these lease agreements are as follows: 2020 $ 114,625 2021 118,065 2022 121,606 2023 125,255 2024 and beyond 140,030 Less: Present value discount (114,442 ) Lease liability $ 505,139 |
Schedule of lease expense | Lease expense for the year ended December 31, 2019 was comprised of the following: Operating lease expense $ 78,034 Short-term lease expense - Variable lease expense - $ 78,034 |
Schedule of Weighted-average remaining lease term | During the year ended December 31, 2019, the Company paid $32,367 lease expense in cash. Weighted-average remaining lease term and discount rate for operating leases are as follows: Weighted-average remaining lease term 4.90 Weighted-average discount rate 8 % During the year ended December 31, 2018, rent expense was $52,029. As of December 31, 2018, future minimum lease payments for office space are as follows: Year ended December 31, 2019 $ 26,844 |
INTELLECTUAL PROPERTY LICENSI_2
INTELLECTUAL PROPERTY LICENSING RIGHTS (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
INTELLECTUAL PROPERTY LICENSING RIGHTS (Tables) | |
Schedule of amortization of intellactual property | The future amortization of the intellectual property are as follows: Year Amount 2020 $ 47,160 2021 47,160 2022 47,160 2023 47,160 2024 35,370 $ 224,010 |
Schedule of amortization of patents | The future amortization of the patents are as follows: Year Amount 2020 $ 1,172 2021 1,169 2022 1,169 2023 1,169 2024 and after 9,057 $ 13,736 |
ACCOUNTS PAYABLE AND ACCRUED _2
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) | |
Schedule of accounts payable and accrued expenses | Accounts payable and accrued expenses consisted of the following as of December 31, 2019 and 2018: 2019 2018 Accounts payable $ 709,353 $ 655,654 Interest payable on notes payable 1,138,157 802,114 Interest payable on notes payable, related parties 125,903 96,120 Deferred insurance 53,967 - Deferred rent - 764 $ 2,027,380 $ 1,554,652 |
STOCK OPTIONS AND WARRANTS (Tab
STOCK OPTIONS AND WARRANTS (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
STOCK OPTIONS AND WARRANTS (Tables) | |
Schedule of stock options | The following table summarizes the stock option activity for the year ended December 31, 2019 and 2018: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2018 478,850 $ 4.00 8.9 $ 326,700 Grants 315,000 14.00 5.0 - Exercised - - - - Expired (2,000 ) 10.00 - - Outstanding at December 31, 2018 791,850 8.09 7.7 1,188,065 Grants 53,280 6.52 2.5 - Exercised - - - - Expired (1,500 ) 20.00 - - Forfeited (20,833 ) 5.75 - - Outstanding at December 31, 2019 822,797 $ 8.03 6.5 $ 244,603 Exercisable at December 31, 2019 814,607 $ 8.04 6.6 $ 244,603 |
Schedule of assumption | In applying the Black-Scholes option pricing model, the Company used the following assumptions: 2019 2018 Risk-free interest rate 2.36% - 2.58% 2.85 % Expected term (years) 1.00 5.00 5.50 Expected volatility 99.85% - 143.11% 135.18 % Expected dividends 0.00 0.00 |
Schedule of information regarding stock options | The following table presents information related to stock options at December 31, 2019: Options Outstanding Options Exercisable Weighted Weighted Average Exercisable Average Exercise Number of Remaining Life Number of Remaining Life Price Options In Years Options In Years $0.01-2.50 330,350 6.5 330,350 6.5 2.51-5.00 35,000 0.6 35,000 0.6 5.01 and up 457,447 7.0 449,257 7.1 822,797 6.5 814,607 6.6 |
Schedule of changes in warrants outstanding | The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company's common stock: Warrants Outstanding Warrants Exercisable Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (Years) $ 20.00 10,000 1.91 $ 20 10,000 1.91 100.00 62,500 1.39 100 62,500 1.39 72,500 1.46 $ 89.0 72,500 1.46 |
Schedule of summary of warrant activity | The following table summarizes the warrant activity for the year ended December 31, 2019: Number of Shares Weighted Average Exercise Price Per Share Outstanding at January 1, 2018 24,300 $ 91.00 Issued 72,500 88.97 Exercised - - Expired (11,550 ) 100.00 Outstanding at December 31, 2018 85,250 $ 79.40 Issued - - Exercised - - Expired (12,750 ) 25.00 Outstanding at December 31, 2019 72,500 $ 89.00 |
NON CONTROLLING INTEREST (Table
NON CONTROLLING INTEREST (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
NON CONTROLLING INTEREST (Tables) | |
Schedule of net loss attributable to non-controlling interest | Net loss attributable to the non-controlling interest for the year ended December 31, 2019: Net loss $ (35,914 ) Average Non-controlling interest percentage of profit/losses 24.2 % Net loss attributable to the non-controlling interest $ (8,691 ) Net loss attributable to the non-controlling interest for the year ended December 31, 2018: Net loss $ (299,533 ) Average Non-controlling interest percentage of profit/losses 24.2 % Net loss attributable to the non-controlling interest $ (72,487 ) |
Schedule of changes in non-controlling interest | The following table summarizes the changes in non-controlling interest for the year ended December 31, 2019: Balance, December 31, 2018 $ (72,487 ) Net loss attributable to the non-controlling interest (8,691 ) Balance, December 31, 2019 (81,178 ) The following table summarizes the changes in non-controlling interest for the year ended December 31, 2018: Balance, December 31, 2017 - Net loss attributable to the non-controlling interest (72,487 ) Balance, December 31, 2018 $ (72,487 ) |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
INCOME TAXES | |
Components of the income tax provisions | The components of the income tax provisions for 2019 and 2018 are as follows: 2019 2018 Current provision: Federal $ - $ - State - - Deferred benefit: Federal - - State - - - - Change in valuation allowance - - Total Provision $ - $ - |
Schedule of different tax rate | The difference between the income tax provision and income taxes computed using the U. S. federal income tax rate of 21% consisted of the following: 2019 2018 Provision at statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 6.98 % 6.98 % Nondeductible and other items (0.07 )% (0.03 )% Change in valuation allowance (27.91 )% (27.95 )% Total (0.0 )% (0.0 )% |
Schedule of deferred taxes | Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred taxes as of December 31, 2019 and 2018 are as follows: 2019 2018 Deferred tax assets: Allowance for doubtful debt $ 7,598 $ 6,926 Stock options issued for services 1,632,377 1,082,303 Net operating loss carryforward 4,766,552 3,126,434 Other 19,516 560 Total deferred tax assets 6,426,043 4,216,223 Deferred tax liabilities: Royalty obligation (708,046 ) - Other (42,915 ) (229,598 ) Total deferred tax liabilities (750,961 ) (229,598 ) Deferred tax asset 5,675,082 3,986,625 Valuation allowance (5,675,082 ) (3,986,625 ) |
BUSINESS (Details Narrative)
BUSINESS (Details Narrative) | 12 Months Ended | |
Dec. 31, 2019 | Jul. 28, 2016 | |
State of Incorporation | Nevada | |
BioCorRx Pharmaceuticals, Inc [Member] | BioCorRx, Inc [Member] | ||
Description of reverse stock split | Effective January 22, 2019, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 100 shares of common stock. As a result, 259,984,655 shares of the Company’s common stock were exchanged for 2,599,847 shares of the Company’s common stock. These consolidated financial statements have been retroactively restated to reflect the reverse stock split (See Note 13). | |
Officer [Member] | BioCorRx Pharmaceuticals, Inc [Member] | ||
Equity issued ownership | 75.80% | |
Noncontrolling Interest [Member] | ||
Equity issued ownership | 24.20% |
SIGNIFICANT ACCOUNTING POLICI_4
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
SIGNIFICANT ACCOUNTING POLICIES (Details) | ||
Sales/access fees | $ 29,150 | $ 122,460 |
Distribution rights income | 207,110 | 246,696 |
Membership/program fees | 3,999 | |
Net sales | $ 240,259 | $ 376,656 |
SIGNIFICANT ACCOUNTING POLICI_5
SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
SIGNIFICANT ACCOUNTING POLICIES (Details 1) | ||
Deferred revenue, short term | $ 134,924 | $ 209,474 |
Deferred revenue, long term | 103,313 | 207,523 |
Cash payments received | 32,349 | |
Net sales recognized | (211,109) | |
Total deferred revenue | $ 238,237 | $ 416,997 |
SIGNIFICANT ACCOUNTING POLICI_6
SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
SIGNIFICANT ACCOUNTING POLICIES (Details 2) | ||
Shares underlying options outstanding | $ 822,797 | $ 791,850 |
Shares underlying warrants outstanding | 72,500 | 85,250 |
Shares underlying convertible notes outstanding | 1,312,500 | |
Convertible preferred stock outstanding | 240,000 | 240,000 |
Total | 1,135,297 | 2,429,600 |
SIGNIFICANT ACCOUNTING POLICI_7
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Jan. 17, 2019 | |
Allowance for doubtful accounts | $ 0 | $ 12,500 | |
Grant funding during the first year | 2,842,430 | ||
Reclassify fair value of warrant liability upon adoption of ASU 2017-11 | 175,975 | ||
Grant funding during the second year | $ 2,831,838 | ||
Impairment of acquired license | 250,000 | ||
Advertising costs | 436,205 | 88,912 | |
Research and development expenses | 1,125,098 | 151,768 | |
Revenue related to access fees | $ 29,150 | ||
Discount rate on face value | 8.00% | ||
Grant income | $ 1,091,061 | ||
Grant funds | $ 932,745 | ||
Royalty obligations description | The Company accounted for this transaction as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the effective interest method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. | ||
Royalty obligations, net | $ 7,171,200 | ||
Description of likelihood settlement | The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. | ||
Eliminated deferred rent upon adoption of ASC 842 | 764 | ||
Notes payable, net of debt discounts | $ 21,480 | $ 569,061 | |
Minimum [Member] | |||
Property plant and equipment estimated useful lives | 5 years | ||
Maximum [Member] | |||
Property plant and equipment estimated useful lives | 15 years | ||
Third Party [Member] | |||
Notes payable, net of debt discounts | $ 125,000 | ||
January 1, 2019 [Member] | |||
Right to use assets upon adoption of ASC 842 | 25,465 | ||
Eliminated deferred rent upon adoption of ASC 842 | 764 | ||
Lease liability upon adoption of ASC 842 | 26,229 | ||
January 22, 2019 [Member] | |||
Notes payable, net of debt discounts | $ 21,480 |
GOING CONCERN AND MANAGEMENT'_2
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details Narrative) | ||
Cash | $ 2,645,852 | $ 279,772 |
Working capital deficit | (495,682) | |
Net cash used in operating activities | (2,937,127) | (1,825,623) |
Proceeds from sale of common stock | 100,000 | $ 1,400,000 |
Subscription receivable | $ 6,000,000 |
PREPAID EXPENSES (Details)
PREPAID EXPENSES (Details) - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
PREPAID EXPENSES (Tables) | ||
Prepaid insurance | $ 81,475 | $ 27,083 |
Prepaid subscription services | 127,208 | 4,375 |
Other prepaid expenses | 4,600 | |
Total | $ 213,283 | $ 31,458 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details) - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
Property and equipment, gross | $ 183,308 | $ 70,525 |
Less accumulated depreciation | (35,008) | (26,156) |
Property and equipment, net | 148,300 | 44,369 |
Leasehold improvement [Member] | ||
Property and equipment, gross | 43,503 | 34,234 |
Office Equipment [Member] | ||
Property and equipment, gross | 5,544 | 5,544 |
Computer Equipment [Member] | ||
Property and equipment, gross | 98,373 | $ 30,747 |
January 1, 2019 [Member] | ||
Property and equipment, gross | $ 35,888 |
PROPERTY AND EQUIPMENT (Detai_2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) | 2 Months Ended | 12 Months Ended | |
Aug. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
PROPERTY AND EQUIPMENT (Details Narrative) | |||
Disposal of office equipment | $ 800 | ||
Loss on sale of fixed assets | 1,902 | ||
Depreciation expense | $ 15,959 | $ 5,390 |
LEASES (Details)
LEASES (Details) | Dec. 31, 2019USD ($) |
LEASES (Details) | |
Total lease liability | $ 505,139 |
Less: short term portion | (76,977) |
Long term portion | $ 428,162 |
LEASES (Details 1)
LEASES (Details 1) | Dec. 31, 2019USD ($) |
LEASES (Details 1) | |
2020 | $ 114,625 |
2021 | 118,065 |
2022 | 121,606 |
2023 | 125,255 |
2024 and beyond | 140,030 |
Less: Present value discount | (114,442) |
Lease liability | $ 505,139 |
LEASES (Details 2)
LEASES (Details 2) | 12 Months Ended |
Dec. 31, 2019USD ($) | |
LEASES (Details 2) | |
Operating lease expense | $ 78,034 |
Short-term lease expense | |
Variable lease expense | |
Total lease expense | $ 78,034 |
LEASES (Details 3)
LEASES (Details 3) | Dec. 31, 2019 |
LEASES (Details 3) | |
Weighted-average remaining lease term | 4 years 10 months 24 days |
Weighted-average discount rate | 8.00% |
LEASES (Details 4)
LEASES (Details 4) | Dec. 31, 2019USD ($) |
LEASES (Details 4) | |
Year ended December 31, 2019 | $ 26,844 |
LEASES (Details Narrative)
LEASES (Details Narrative) - USD ($) | Jul. 15, 2019 | Feb. 14, 2019 | Dec. 31, 2019 | Dec. 31, 2018 |
Lease commencement date | Jul. 1, 2016 | |||
Extension of lease term description | The Company extended the term of its lease for an additional 63 months beginning November 1, 2019. The extended term expires on January 31, 2025. The extended lease has escalating payments from $9,505 per month to $11,018 per month. | the Company extended the term of its lease for an additional 63 months beginning July 1, 2019 (at expiry of the original lease). The extended term expires on September 30, 2024. The extended lease has escalating payments from $5,522 per month to $6,552 per month. | ||
Lease expiration date | Jun. 30, 2019 | |||
Right to use assets and lease liability | $ 299,070 | |||
Total lease expense | $ 32,367 | |||
Eliminated deferred rent upon adoption of ASC 842 | $ 764 | |||
Manufacturing Equipment [Member] | ||||
Right to use assets and lease liability | 201,263 | |||
On January 1, 2019 [Member] | ||||
Lease liability upon adoption of ASC 842 | 26,229 | |||
Eliminated deferred rent upon adoption of ASC 842 | 764 | |||
Right to use assets upon adoption of ASC 842 | $ 25,465 |
INTELLECTUAL PROPERTY LICENSI_3
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details) | Dec. 31, 2019USD ($) |
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details) | |
2020 | $ 47,160 |
2021 | 47,160 |
2022 | 47,160 |
2023 | 47,160 |
2024 | 35,370 |
Total future amortization of the intellectual property | $ 224,010 |
INTELLECTUAL PROPERTY LICENSI_4
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details 1) | Dec. 31, 2019USD ($) |
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details 1) | |
2020 | $ 1,172 |
2021 | 1,169 |
2022 | 1,169 |
2023 | 1,169 |
2024 and after | 9,057 |
Total future amortization of the patents | $ 13,736 |
INTELLECTUAL PROPERTY LICENSI_5
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($) | Oct. 12, 2018 | Aug. 20, 2018 | Dec. 31, 2019 | Dec. 31, 2018 |
Amortization expense | $ 1,464 | $ 11,990 | ||
Estimated useful lives | 13 years | 5 years | ||
Accumulated amortization | $ 11,990 | |||
Patents | $ 1,464 | |||
Aggregate purchase price, value | $ 236,000 | |||
Aggregate purchase price, Shares | 20,000 | |||
cash paid for acquisition | $ 10,000 | |||
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member] | ||||
Amortization expense | $ 1,464 | |||
Estimated useful lives | 13 years | |||
Patent acquired | $ 15,200 | |||
February 14, 2019 [Member] | ||||
Aggregate purchase price, value | $ 236,000 | |||
Aggregate purchase price, Shares | 20,000 | |||
cash paid for acquisition | $ 10,000 |
ACCOUNTS PAYABLE AND ACCRUED _3
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) | ||
Accounts payable | $ 709,353 | $ 655,654 |
Interest payable on notes payable | 1,138,157 | 802,114 |
Interest payable on notes payable, related parties | 125,903 | 96,120 |
Deferred insurance | 53,967 | |
Deferred rent | 764 | |
Accounts payable and accrued expenses | $ 2,027,380 | $ 1,554,652 |
NOTES PAYABLE (Details Narrativ
NOTES PAYABLE (Details Narrative) - USD ($) | 1 Months Ended | 4 Months Ended | 12 Months Ended | ||||
Jan. 26, 2019 | Nov. 15, 2018 | Jul. 26, 2018 | Jan. 26, 2018 | Apr. 26, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Notes payable, net of debt discounts | $ 21,480 | $ 569,061 | |||||
Debt discount to current period interest expense | $ 127,419 | $ 17,242 | |||||
Interest rate | 8.00% | ||||||
Common stock, shares issued | 2,500 | 5,326,852 | 2,597,347 | ||||
Warrants issued | 5,000 | ||||||
Warrant exercise price per share | $ 20 | ||||||
Debt discount | $ 144,661 | $ 783,650 | $ 1,530,470 | ||||
Expected life | 3 years | 5 years 5 months 30 days | |||||
Interest expense | $ 8,110 | $ 53,288 | |||||
Promissory notes issued | 275,000 | ||||||
Proceeds received | 250,000 | ||||||
Repayment of debt | $ 22,000 | ||||||
Original issuance discount | $ 25,000 | ||||||
Common stock issued in connection with note payable extension, Shares | 1,000 | ||||||
Common stock issued with loan extension | $ 12,000 | ||||||
Note 1 [Member] | |||||||
Interest rate | 8.00% | ||||||
Interest expense | $ 10,000 | ||||||
Unsecured promissory notes | $ 125,000 | ||||||
Shares issued for debt | 50,000 | ||||||
Shsres issued for debt, value | $ 12,750 | ||||||
Principal and interest due date | Jul. 26, 2018 | ||||||
Common stock issued in connection with note payable extension, Shares | 1,000 | 100,000 | |||||
Common stock issued with loan extension | $ 7,500 | ||||||
Minimum [Member] | |||||||
Expected life | 1 year | ||||||
Volatility | 176.31% | ||||||
Risk free rate | 2.78% | ||||||
Stock price | $ 7.20 | ||||||
Maximum [Member] | |||||||
Expected life | 5 years | ||||||
Volatility | 177.01% | ||||||
Risk free rate | 2.91% | ||||||
Stock price | $ 7.30 |
CONVERTIBLE NOTES PAYABLE (Deta
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($) | Jun. 10, 2016 | Nov. 15, 2018 | Dec. 31, 2019 | Dec. 31, 2018 |
Amortization of debt discount | $ 656,231 | $ 1,487,728 | ||
Interest expense | $ 389,330 | 332,800 | ||
Shares issued opon conversion of debt | 2,227,575 | |||
Additional investment | $ 1,660,000 | |||
Interest expense | (1,622,426) | $ (1,959,207) | ||
Interest rate | 8.00% | |||
March, 2020 [Member] | ||||
Conversion interest payable | $ 1,138,157 | |||
BICX Holding Company LLC [Member] | ||||
Shares issued opon conversion of debt | 2,227,575 | |||
Description of conversion agreement | During the period commencing on October 1, 2019 and ending six (6) months following the initial closing of the Company’s intended public offering of its securities to raise gross proceeds to the Company of at least $10,000,000 (subject to adjustment in the Company’s sole discretion) (the “Public Offering”). In the event that the intended public offering is terminated or abandoned prior to closing then the lock-up shall expire upon the later of the date which is six (6) months from September 30, 2019 or thirty (30) days from the date of such termination or abandonment. | |||
Convertible promissory note | $ 2,500,000 | |||
Maturity period | Mar. 3, 2020 | |||
Interest rate | 8.00% |
NOTES PAYABLE-RELATED PARTIES (
NOTES PAYABLE-RELATED PARTIES (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Nov. 15, 2018 | Jan. 26, 2018 | Jan. 22, 2013 | Dec. 31, 2019 | Dec. 31, 2018 | |
Interest payable on notes payable, related parties | $ 125,903 | $ 96,120 | |||
Interest expense on notes payable, related parties | 29,783 | 29,071 | |||
Outstanding principal balance on issuance of promissory note | 163,610 | 163,610 | |||
Interest rate | 8.00% | ||||
Kent Emry [Member] | |||||
Due from related party | 1,500 | 1,500 | |||
Maturity date | Jan. 1, 2018 | ||||
Interest rate | 12.00% | ||||
Principal payments (monthly) | $ 6,650 | ||||
Joe Galligan [Domain] | |||||
Principal and interest due date | Jul. 26, 2018 | ||||
Shsres issued for debt, value | $ 12,750 | ||||
Interest rate | 8.00% | ||||
Shares issued for debt | 50,000 | ||||
Due from related party | 125,000 | $ 125,000 | |||
Unsecured promissory notes | $ 125,000 |
ROYALTY OBLIGATIONS, NET (Detai
ROYALTY OBLIGATIONS, NET (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
ROYALTY OBLIGATIONS, NET (Details Narrative) | ||
Amortization of discount on royalty obligation | $ 358,882 | |
Royalty agreements description | (i) Each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”). |
STOCKHOLDERS' EQUITY (DEFICIT)
STOCKHOLDERS' EQUITY (DEFICIT) (Details Narrative) - USD ($) | May 10, 2018 | Apr. 28, 2019 | Feb. 28, 2019 | Jan. 22, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2019 | Dec. 30, 2018 | Nov. 15, 2018 |
Common stock exchange description | The Company is authorized to issue from five hundred twenty five million six hundred thousand (525,600,000) shares to seven hundred fifty million six hundred thousand (750,600,000) shares and increasing the number of authorized shares of common stock from five hundred and twenty five million (525,000,000) shares of common stock, $0.001 par value, to seven hundred and fifty million (750,000,000) shares of common stock. | As a result, 259,984,655 shares of the Company’s common stock were exchanged for 2,599,847 shares of the Company’s common stock. | |||||||
Preferred stock, shares authorized | 600,000 | 600,000 | |||||||
Common stock issued aggregate,Shares | $ 2,227,575 | ||||||||
Convertible amount of aggregate shares issued | $ 4,160,000 | ||||||||
Common stock shares issued for services, shares | 10,000 | ||||||||
Common stock issued for distribution agreement | 10,000 | ||||||||
Common stock issued in connection with note payable , Shares | 6,000 | ||||||||
Common stock issued in connection with note payable , Amount | $ 61,750 | ||||||||
Common stock issued in connection with note payable extension, Shares | 1,000 | ||||||||
Common stock shares issued during the period | 75,000 | ||||||||
Common stock issued in connection with note payable extension, value | $ 12,000 | ||||||||
Common stock subscriptions, value | $ 100,000 | $ 1,150,000 | |||||||
Common stock issued to settle outstanding accounts payable, shares | 4,236 | ||||||||
Common stock subscriptions, shares | 22,222 | ||||||||
Common stock issued to settle outstanding accounts payable, value | $ 29,653 | ||||||||
Warrants issued | 57,500 | ||||||||
Exercised price | $ 100 | ||||||||
Common stock issued for interest, shares | 3,842 | ||||||||
Price per unit | $ 20 | ||||||||
Common stock issued for interest, value | $ 21,000 | ||||||||
cash paid for acquisition | $ 10,000 | ||||||||
Aggregate purchase price, Shares | 20,000 | ||||||||
Aggregate purchase price, value | $ 236,000 | ||||||||
Common stock shares issued for services, value | $ 57,730 | ||||||||
Common stock for services rendered, Value | $ 271,050 | ||||||||
Common stock for services rendered, Shares | 75,017 | ||||||||
Common stock, shares issued | 5,326,852 | 2,597,347 | 2,500 | ||||||
Proceeds from issuance of common stock | $ 100,000 | $ 1,400,000 | |||||||
February 1, 2015 [Member] | Mr Emry [Member] | |||||||||
Common stock shares issued for services, value | $ 12,000 | ||||||||
Series A Preferred Stock [Member] | |||||||||
Preferred stock, shares authorized | 80,000 | 80,000 | |||||||
Preferred stock, shares outstanding | 80,000 | 80,000 | |||||||
Preferred stock, shares issued | 80,000 | 80,000 | |||||||
Convertible preferred stock description | Each share of Series A preferred stock is entitled to one thousand (1,000) votes and is convertible into one share of common stock. 30,000 shares of Series A Preferred Stock are owned by management. The Series A Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series A. Each share of Series A Preferred Stock may be converted, at the option of the holder each share of Series A Preferred Stock may be converted equal to one (1) fully paid and nonassessable share of Common Stock, par value $0.001. | Each share of Series A preferred stock is entitled to one thousand (1,000) votes and is convertible into one share of common stock. 30,000 shares of Series A Preferred Stock are owned by management. The Series A Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series A. Each share of Series A Preferred Stock may be converted, at the option of the holder each share of Series A Preferred Stock may be converted equal to one (1) fully paid and nonassessable share of Common Stock, par value $0.001. | |||||||
Common Stock [Member] | |||||||||
Proceeds from issuance of common stock | $ 1,400,000 | ||||||||
Series B Preferred Stock [Member] | |||||||||
Preferred stock, shares authorized | 160,000 | 160,000 | |||||||
Preferred stock, shares outstanding | 160,000 | 160,000 | |||||||
Preferred stock, shares issued | 160,000 | 160,000 | |||||||
Convertible preferred stock description | Each share of Series B stock is entitled to two thousand (2,000) votes and is convertible into one share of common stock. 120,000 shares of Series B Preferred Stock are owned by management. The Series B Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series B. Each share of Series B Preferred Stock may be converted, at the option of the holder each share of Series B Preferred Stock may be converted equal to one (1) fully paid and nonassessable share of Common Stock, par value $0.001. | Each share of Series B stock is entitled to two thousand (2,000) votes and is convertible into one share of common stock. 120,000 shares of Series B Preferred Stock are owned by management. The Series B Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series B. Each share of Series B Preferred Stock may be converted, at the option of the holder each share of Series B Preferred Stock may be converted equal to one (1) fully paid and nonassessable share of Common Stock, par value $0.001. | |||||||
Director [Member] | |||||||||
Common stock for services rendered, Value | $ 100,000 | ||||||||
Common stock for services rendered, Shares | 29,111 | ||||||||
Subscription and Royalty Agreements [Member] | |||||||||
Proceeds from common stock | 600,000 | ||||||||
Common stock, shares issued | 400,000 |
STOCK OPTIONS AND WARRANTS (Det
STOCK OPTIONS AND WARRANTS (Details) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Risk-free interest rate | 2.85% | |
Expected term (years) | 3 years | 5 years 5 months 30 days |
Expected volatility | 135.18% | |
Expected dividends | 0.00% | 0.00% |
Minimum [Member] | ||
Risk-free interest rate | 2.36% | |
Expected term (years) | 1 year | |
Expected volatility | 99.85% | |
Maximum [Member] | ||
Risk-free interest rate | 2.58% | |
Expected term (years) | 5 years | |
Expected volatility | 143.11% |
STOCK OPTIONS AND WARRANTS (D_2
STOCK OPTIONS AND WARRANTS (Details 1) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Number of Shares | ||
Outstanding, Beginning | 791,850 | 478,850 |
Grants | 53,280 | 315,000 |
Exercised | ||
Expired | (1,500) | (2,000) |
Forfeited | (20,833) | |
Outstanding, Ending | 822,797 | 791,850 |
Exercisable at End of Year | 814,607 | |
Weighted Average Exercise Price | ||
Outstanding, Beginning | $ 8.09 | $ 4 |
Grants | 6.52 | 14 |
Exercised | ||
Expired | 20 | 10 |
Forfeited | 5.75 | |
Outstanding, Ending | 8.03 | |
Exercisable at End of Year | $ 8.04 | $ 8.09 |
Weighted Average Remaining Contractual Term | ||
Outstanding, Beginning | 7 years 8 months 12 days | 8 years 10 months 24 days |
Grants | 2 years 6 months | 5 years |
Outstanding at End of Year | 6 years 6 months | 7 years 8 months 12 days |
Exercisable at End of Year | 6 years 7 months 6 days | |
Aggregate Intrinsic Value | ||
Outstanding, Beginning | $ 1,188,065 | $ 326,700 |
Grants | ||
Expired | ||
Outstanding at End of Year | 244,603 | $ 1,188,065 |
Exercisable at End of Year | $ 244,603 |
STOCK OPTIONS AND WARRANTS (D_3
STOCK OPTIONS AND WARRANTS (Details 2) | 12 Months Ended |
Dec. 31, 2019shares | |
Exercisable, Number of Options | 814,607 |
Options Exercisable [Member] | |
Weighted average remaining life in years | 6 years 7 months 6 days |
Exercisable, Number of Options | 814,607 |
Options Exercisable [Member] | 5.01 And Up [Member] | |
Weighted average remaining life in years | 7 years 1 month 6 days |
Exercisable, Number of Options | 449,257 |
Options Exercisable [Member] | 2.51-5.00 [Member] | |
Weighted average remaining life in years | 7 months 6 days |
Exercisable, Number of Options | 35,000 |
Options Exercisable [Member] | 0.01-2.50 [Member] | |
Weighted average remaining life in years | 6 years 5 months 30 days |
Exercisable, Number of Options | 330,350 |
Options Outstanding [Member] | |
Weighted average remaining life in years | 6 years 5 months 30 days |
Number of options | 822,797 |
Options Outstanding [Member] | 5.01 And Up [Member] | |
Weighted average remaining life in years | 7 years |
Number of options | 457,447 |
Options Outstanding [Member] | 2.51-5.00 [Member] | |
Weighted average remaining life in years | 7 months 6 days |
Number of options | 35,000 |
Options Outstanding [Member] | 0.01-2.50 [Member] | |
Weighted average remaining life in years | 6 years 5 months 30 days |
Number of options | 330,350 |
STOCK OPTIONS AND WARRANTS (D_4
STOCK OPTIONS AND WARRANTS (Details 3) | 12 Months Ended |
Dec. 31, 2019$ / sharesshares | |
Number exercisable | 814,607 |
Warrant [Member] | |
Number outstanding | 72,500 |
Weighted average remaining contractual life | 1 year 5 months 16 days |
Weighted average exercise price | $ / shares | $ 89 |
Number exercisable | 72,500 |
Weighted average remaining contractual life, Exercisable | 1 year 5 months 16 days |
Warrant [Member] | 20.00 [Member] | |
Exercise Prices | $ / shares | $ 20 |
Number outstanding | 10,000 |
Weighted average remaining contractual life | 1 year 10 months 28 days |
Weighted average exercise price | $ / shares | $ 20 |
Number exercisable | 10,000 |
Weighted average remaining contractual life, Exercisable | 1 year 10 months 28 days |
Warrant [Member] | 100.00 [Member] | |
Exercise Prices | $ / shares | $ 100 |
Number outstanding | 62,500 |
Weighted average remaining contractual life | 1 year 4 months 21 days |
Number exercisable | 62,500 |
Weighted average remaining contractual life, Exercisable | 1 year 4 months 21 days |
STOCK OPTIONS AND WARRANTS (D_5
STOCK OPTIONS AND WARRANTS (Details 4) - $ / shares | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Number of Shares | ||
Issued | 53,280 | 315,000 |
Exercised | ||
Expired | (1,500) | (2,000) |
Outstanding, Ending | 822,797 | 791,850 |
Weighted Average Exercise Price | ||
Issued | $ 6.52 | $ 14 |
Expired | 20 | 10 |
Outstanding, Ending | $ 8.03 | |
Warrant [Member] | ||
Number of Shares | ||
Outstanding, Beginning | 85,250 | 24,300 |
Issued | 72,500 | |
Exercised | ||
Expired | (12,750) | (11,550) |
Outstanding, Ending | 72,500 | 85,250 |
Weighted Average Exercise Price | ||
Outstanding, Beginning | $ 79.40 | $ 91 |
Issued | 88.97 | |
Exercised | ||
Expired | 25 | 100 |
Outstanding, Ending | $ 89 | $ 79.40 |
STOCK OPTIONS AND WARRANTS (D_6
STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Stock compensation expense | $ 1,694,653 | $ 2,349,427 |
Reclassify fair value of warrant liability upon adoption of ASU 2017-11 | $ 175,975 | |
Stock compensation expense unamortized | $ 26,999 | |
Weighted average remaining life | 10 years 7 months 6 days | |
Number of stock option shares, granted | 53,280 | 315,000 |
Stock Options [Member] | ||
Number of stock option shares, granted | 53,280 | |
Option grants value | $ 233,111 | |
2018 Equity Incentive Plan [Member] | ||
Option grantable | 102,553 | |
Common stock shares issued | 450,000 | |
Plan termination term | 10 years | |
Number of stock option shares, granted | 347,447 | |
2016 Equity Incentive Plan [Member] | ||
Option grantable | 325,900 | |
Common stock shares issued | 656,250 | |
Plan termination term | 10 years | |
Number of stock option shares, granted | 330,350 | |
2014 Equity Incentive Plan [Member] | ||
Option grantable | 145,879 | |
Common stock shares issued | 290,879 | |
Plan termination term | 10 years | |
Number of stock option shares, granted | 145,000 | |
Warrant [Member] | ||
Number of stock option shares, granted | 72,500 | |
Warrant [Member] | 79.40 [Member] | ||
Intrinsic value of the vested stock options price | $ 2.75 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 12 Months Ended | |||
Dec. 31, 2019 | Dec. 31, 2018 | Mar. 27, 2020 | Jul. 28, 2016 | |
Related party payables | $ 391,209 | $ 32,318 | ||
Unpaid balance | 210 | |||
Proceeds from royalty | 6,000,000 | |||
Common stock for services rendered, Value | $ 271,050 | |||
Common stock for services rendered, Shares | 75,017 | |||
Director [Member] | ||||
Ownership percentage held by former officers | 24.20% | |||
Common stock for services rendered, Value | $ 100,000 | |||
Common stock for services rendered, Shares | 29,111 | |||
Ownership percentage held by Company | 75.80% | |||
FFE [Member] | ||||
Base salary | $ 175,000 | |||
Monthly remuneration | 14,583 | |||
Consulting fees | 250,000 | 200,625 | ||
Director Agreement [Member] | ||||
Common stock issuable value | 5,000 | |||
Compensation for services | 15,000 | |||
Joseph Galligan [Member] | ||||
Monthly remuneration | 6,250 | |||
Consulting fees | 68,750 | 0 | ||
Mr. Tom Welch, VP of Operations [Member] | ||||
Base salary | 150,000 | 175,000 | ||
Monthly remuneration | 12,500 | |||
Consulting fees | 150,000 | 167,417 | ||
Soupface LLC [Member] | ||||
Base salary | 190,000 | |||
Monthly remuneration | 15,833 | |||
Consulting fees | 265,000 | 212,500 | ||
PARS [Member] | ||||
Unpaid balance | 0 | 32,318 | ||
Monthly remuneration | 14,583 | |||
Consulting fees | 0 | $ 0 | ||
Subsequent Event [Member] | Mr. Brady Granier [Member] | ||||
Base salary | 215,000 | |||
Subsequent Event [Member] | Ms. Lourdes Felix [Member] | ||||
Base salary | $ 190,000 |
CONCENTRATIONS (Details Narrati
CONCENTRATIONS (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Sales Revenue [Member] | ||
Concentration risk, percentage | 86.00% | 73.00% |
Sales Revenue [Member] | Customer One [Member] | ||
Concentration risk, percentage | 33.00% | 13.00% |
Sales Revenue [Member] | Customer Two [Member] | ||
Concentration risk, percentage | 21.00% | 18.00% |
Sales Revenue [Member] | Customer Three [Member] | ||
Concentration risk, percentage | 17.00% | 22.00% |
Sales Revenue [Member] | Customer Four [Member] | ||
Concentration risk, percentage | 15.00% | 20.00% |
Accounts Receivable [Member] | ||
Concentration risk, percentage | 100.00% | 93.00% |
Major customer, accounts receivable | $ 750 | |
Accounts Receivable [Member] | Customer One [Member] | ||
Concentration risk, percentage | 44.00% | |
Accounts Receivable [Member] | Customers Two [Member] | ||
Concentration risk, percentage | 17.00% | |
Accounts Receivable [Member] | Customers Three [Member] | ||
Concentration risk, percentage | 33.00% |
NON CONTROLLING INTEREST (Detai
NON CONTROLLING INTEREST (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Net loss attributable to the non-controlling interest | $ (8,691) | $ (72,487) |
BioCorRx Pharmaceuticals, Inc [Member] | ||
Net loss | (35,914) | (299,533) |
Net loss attributable to the non-controlling interest | $ (8,691) | $ (72,487) |
Average Non-controlling interest percentage of profit/losses | 24.20% | 24.20% |
NON CONTROLLING INTEREST (Det_2
NON CONTROLLING INTEREST (Details 1) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
NON CONTROLLING INTEREST (Details 1) | ||
Beginning Balance | $ (72,487) | |
Net loss attributable to the non-controlling interest | (8,691) | (72,487) |
Ending Balance | $ (81,178) | $ (72,487) |
NON CONTROLLING INTEREST (Det_3
NON CONTROLLING INTEREST (Details Narrative) - BioCorRx Pharmaceuticals, Inc [Member] - USD ($) | Dec. 31, 2019 | Jul. 28, 2016 |
Ownership percentage hold by former officers | 24.20% | |
Ownership percentage hold by company | 75.80% | |
Licensing rights, carrying value | $ 250,000 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | Dec. 10, 2015 | Jul. 31, 2019 | May 30, 2019 | Mar. 28, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 27, 2020 |
Research and development expenses | $ 382,915 | $ 382,915 | |||||
Description for compensation for services under agreement | two advisory board members shall be issued common stock equivalent to $5,000 the last day of such quarter when meetings are held; (ii) one consultant shall receive common stock equivalent to $6,250 on the last day of each month; (iii) one consultant shall receive a renumeration amount of $10,000-$12,000 per month with an earn out potential of 1% of the Companys majority owned subsidiary, BioCorRx Pharmaceuticals based on certain factors; (iv) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; and (v) one consultant shall receive common stock equivalent to $6,667 on the last day of each month (vi) one consultant shall receive a renumeration amount of $5,500 per month | ||||||
Common stock issued upon convertible debt | 2,227,575 | ||||||
Common stock shares issued for services | 10,000 | ||||||
Office Equipment [Member] | |||||||
Common stock shares issued for services | 1,658 | ||||||
Lucido [Member] | |||||||
Common stock, Shares issued | 200,000 | ||||||
Alpine Creek [Member] | |||||||
Payables to Alpine Creek | $ 1,215,000 | $ 85,805 | |||||
Payable commitment description | In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories. | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. | |||||
Payable per treatment sold | $ 100 | ||||||
Royalty due | $ 3,503 | ||||||
Profit holding percentage | 50.00% | ||||||
BICX Holding Company LLC [Member] | |||||||
Common stock issued upon convertible debt | 2,227,575 | ||||||
Convertible Promissory Note | $ 4,160,000 | ||||||
Conversion agreement description | Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. | ||||||
Issuance price | $ 2 | ||||||
Gross proceeds | $ 10,000,000 | ||||||
Charles River Laboratories, Inc. [Member] | Subsequent Event [Member] | |||||||
Consideration amount | $ 3,024,476 | ||||||
February 20, 2020 [Member] | Statement of Work Pursuant [Member] | |||||||
Consideration amount | $ 894,600 | ||||||
Manufacturing Agreement [Member] | |||||||
Estimated cost | 578,500 | ||||||
Consideration amount | 343,648 | ||||||
Galligan Subscription and Royalty Agreement [Member] | |||||||
Common stock, Shares issued | 200,000 | ||||||
Lucido Subscription and Royalty Agreement [Member] | |||||||
Development and expansion expenses amount | $ 3,000,000 | ||||||
Subscription and royalty agreement description | Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”) | ||||||
Description for the use of proceeds under agreement | The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Current provision: | ||
Federal | ||
State | ||
Deferred benefit: | ||
Federal | ||
State | ||
Total | ||
Change in valuation allowance | ||
Total Provision |
INCOME TAXES (Details 1)
INCOME TAXES (Details 1) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
INCOME TAXES (Details 1) | ||
Provision at statutory rate | 21.00% | 21.00% |
State taxes, net of federal benefit | 6.98% | 6.98% |
Nondeductible and other items | (0.07%) | (0.03%) |
Change in valuation allowance | 27.91% | 27.95% |
Total | 0.00% | 0.00% |
INCOME TAXES (Details 2)
INCOME TAXES (Details 2) - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
Deferred tax assets: | ||
Allowance for doubtful debt | $ 7,598 | $ 6,926 |
Stock options issued for services | 1,632,377 | 1,082,303 |
Net operating loss carry forwards | 4,766,552 | 3,126,434 |
Other | 19,516 | 560 |
Total deferred tax assets | 6,426,043 | 4,216,223 |
Deferred tax liabilities: | ||
Royalty obligation | (708,046) | |
Other | (42,915) | (229,598) |
Total deferred tax liabilities | (750,961) | (229,598) |
Deferred tax asset | 5,675,082 | 3,986,625 |
Valuation allowance | $ (5,675,082) | $ (3,986,625) |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) | 12 Months Ended |
Dec. 31, 2019USD ($) | |
INCOME TAXES (Details Narrative) | |
Federal net operating losses carryforward expiry period | 2033 |
Federal net operating losses carryforward | $ 17,000,000 |
Cumulative change in ownership | 50.00% |
Valuation allowances adjustments | $ 1,688,457 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||
Feb. 28, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Jan. 17, 2019 | |
Grant funding during the second year | $ 2,831,838 | |||
Common stock value | $ 5,327 | $ 2,597 | ||
Common stock shares issued for consulting services | 10,000 | |||
Subsequent Event [Member] | Common Stock [Member] | ||||
Common stock value | $ 35,776 | |||
Common stock shares issued for consulting services | 12,905 |